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Abstract
This prospective cohort study across 12 Canadian transplant centres evaluated the costs
incurred by 912 living kidney donors. Expenses and resources were captured to 3-months
post-donation, and micro-costing was used to appraise the costs incurred by donors.
Living kidney donors incurred average total costs of $4790, and direct and indirect costs
of $2110 and $2679, respectively. 13.3% of donors incurred total costs exceeding
$10,000, and 8.6% of donors incurred costs >25% of their annual household income.
Costs incurred by spousal donors were not significantly different from either unrelated or
closely related donors. Similarly, costs incurred by kidney paired donors were not
significantly different from other donors. In multivariable analyses, living >100 km from
the transplant evaluation centre and being employed were associated with higher total
costs. In conclusion, many living kidney donors incur substantial costs associated with
donation, and our findings can be used to improve the donation experience.

Keywords
Living kidney donation, kidney transplantation, cost analysis, prospective cohort study,
micro-costing, reimbursement policy
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Chapter 1

1

Introduction

Over 40,000 Canadians live with end-stage kidney disease (ESKD), a number that has
more than doubled in the last two decades.2,3 Patients living with kidney failure have a 5year survival rate of just 38%: comparable to rates for many advanced cancers. 4 Kidney
transplantation is the preferred treatment for end-stage kidney disease and, compared to
dialysis, results in increased long-term survival, improved quality of life, and reduced
health care costs.5-7 Unfortunately, supply has not met the demand; patients wait several
years to receive a deceased donor kidney transplant, and 2-3% of patients die waiting
each year.8
In response to the shortage of deceased donor kidneys, living donor kidney
transplantation has emerged to fill in the gap, accounting for ~40% of kidney transplants
in Canada today.9,10 Compared to deceased donation, living kidney transplants offer
ESKD patients the measurable benefits of decreased time on dialysis and better graft
survival.11,12 However, the number and rate of living donor kidney transplants has
stagnated over the last decade despite growing waiting lists and the implementation of
kidney paired donation programs across Canada. 9,13
Living kidney donors incur financial costs throughout the donation process in the form of
direct (travel, accommodation, parking, and medication) and indirect costs (lost income
and lost productivity).14,15 These financial costs may pose a barrier to donation for some
candidates.16 There is consensus within the transplant community that living kidney

2

donation should be a financially neutral act and it is just that donor costs associated with
transplantation be reimbursed.17 These costs incurred by donors occur in the context of
their gift improving the health of the recipient, and substantial healthcare savings in
averted dialysis costs (every 100 living kidney donor transplants over a 5-year period
save the healthcare system about $25 million).2,18,19 Given this, many argue that the full
extent of economic consequences to donors should be mitigated, including home and
work productivity losses.20 The burden of these out-of-pocket costs may dissuade donors;
presently, socioeconomically disadvantaged patients with kidney failure are less likely to
receive a living donor kidney than wealthier patients.21 In response, Canada implemented
its first programs to reimburse donors for their expenses in 2009; nevertheless, the
policies that govern these programs lack evidence-based criteria and vary considerably
across provinces.22
Many prior efforts to describe the economic costs and financial burden of living kidney
donation have been limited by small sample sizes, the retrospective nature of the studies,
and incomplete or inadequate cost-capturing.15 There is an opportunity to better
characterize the costs of living kidney donation from the perspective of the donor: a
critical component of donor education and a truly informed consent process ensuring
patients understand the economic consequences of donation. Given the gaps in the
literature, there is a clear need to accurately quantify the costs of living kidney
transplantation from the donor perspective in a rigorous prospective study.

3

Aim and Scope
The overarching aim of this research is to gain a holistic understanding of the economic
costs incurred by Canadian living kidney donors. This understanding can be used to
support informed consent, and to inform strategies that address the financial barriers to
donation which includes an evidence-based reimbursement policy. This research uses a
prospective design, with comprehensive cost-capturing instruments, and a sample size
five times larger than the leading study in the field.
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Chapter 2

2

Literature Review
End-Stage Kidney Disease

End-stage kidney disease (ESKD), or kidney failure, occurs as a result of reduction in
renal function to a point where the kidneys are no longer able to sustain day-to-day life. 23
ESKD is the final and most severe stage of chronic kidney disease. 24,25 The 2012 Kidney
Disease Improving Global Outcomes guidelines for evaluating and managing kidney
disease defined ESKD as a reduction in glomerular filtration rate (GFR) to less than 15
mL/min/1.73 m2 or dysfunction necessitating renal replacement therapy (dialysis or a
kidney transplant).25 GFR is a measure of kidney function describing the flow rate of
filtered fluid through the kidney; a GFR is > 90 mL/min/1.73 m 2 is considered normal or
healthy.25,26 Diabetes as a cause of kidney disease is growing and accounts for nearly half
of the primary diagnoses of Canadian patients with ESKD. 9
In a report by the Canadian Organ Replacement Register, the burden of kidney failure is
growing; the prevalence of ESKD has increased nearly 141% since 1993 and continues to
climb.3 By the end of 2013, over 40,000 Canadians were living with kidney failure,
compared to less than 15,000 just 20 years earlier.2,3 Between 1993 and 2001, the
incidence of ESKD among older patients doubled, and though these rates have stabilized
in recent years, there were 5431 Canadians newly diagnosed with ESKD in 2012, almost
double the number diagnosed in 1993.3
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For all patients with incident ESKD, the 5-year unadjusted survival rate is just 38%,
similar to the survival rates for many advanced cancers. 4 In patients over the age of 65,
the 5-year survival is only 18%.27 In 2013, more than half of incident cases of ESKD in
Canada were among patients aged 65 and older.3 Beyond the poor mortality outcomes for
kidney failure, patients have a markedly reduced health related quality of life. 28-30 In a
prospective study of Canadian ESKD patients, half reported problems with pain, and of
these patients, three-quarters reported that their pain was ineffectively managed. 31
Treating kidney failure is resource intensive for both the healthcare system and for
patients. In 2002, over 1.2% of total Canadian healthcare expenditures were devoted to
caring for patients with ESKD, while only 0.092% of the population has kidney
failure.32,33 Beyond this, many patients experience restrictions in their professional and
personal lives, placing a heavy financial burden on patients, their families, and the
healthcare system.34-36

Renal Replacement Therapy
The treatment for end-stage kidney disease is renal replacement therapy (RRT), where
the blood-filtering function of the kidneys is replaced by way of dialysis or a kidney
transplant. The following sections will discuss the prevalent RRT modalities in Canada
and their outcomes from the perspective of patients with kidney failure.
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2.2.1 Dialysis
Dialysis is a type of renal replacement therapy involving the removal of wastes and
excess water by diffusing solutes and filtering fluid across a semi-permeable membrane.
There are two main types of dialysis: hemodialysis (HD) and peritoneal dialysis (PD).
Hemodialysis works by removing waste products and excess fluid from blood by
circulating it outside the body through an external filter. 37 In Canada, hemodialysis is the
most common form of RRT: 77% of patients starting renal replacement therapy for
ESKD in 2013 initiated treatment on hemodialysis.9 The 5-year survival rate for HD is
44.8%, however, survival varies across patient age and primary diagnosis. 9 Typically,
patients receive hemodialysis 3-4 times a week for sessions of 3-5 hours in length.
Transportation costs and productivity losses due to hemodialysis are a financial burden
felt both by patients and their caregivers. A small Canadian randomized trial found that
the overall patient-borne cost for in-centre hemodialysis is $3104 over a 6 month period,
while the annual healthcare cost of treating a patient with HD ranges from $90,000 to
$107,000 to the public insurer.33,38
In peritoneal dialysis (PD), a glucose solution is passed into the peritoneal cavity to
facilitate the removal of waste and excess fluid; the peritoneal membrane acts as the
semi-permeable membrane.37 About 10% of Canadian ESKD patients are treated with
peritoneal dialysis, and 19.4% initiated treatment on PD in 2013. 9 Some studies (but not
others) have suggested that peritoneal dialysis is associated with a survival advantage
compared with in-centre hemodialysis, and in Canada, the 5-year survival rate for PD is
54.5%.9,39-41 However, uncertainty in the relative efficacy of the two dialysis modalities
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remains due to a lack of randomized trials comparing the two directly. Peritoneal dialysis
is administered at home by the patient and offers more control and independence than
hemodialysis. The overall healthcare cost of PD also appears to be appreciably less than
that of HD, with the cost of treating a single patient at $56,000 per year. 33

2.2.2 Transplantation
Kidney transplantation is the preferred renal replacement therapy for most patients with
kidney failure. In 2013, 42.5% of Canadian patients living with ESKD had functioning
kidney transplants and 3.9% of patients with kidney failure initiated therapy by way of
transplant (referred to as a pre-emptive kidney transplant). 9
Kidney transplantation is dependent on the availability of organs from either deceased
donors or living donors. Donor kidneys and recipients are assessed for compatibility
based on blood typing, serum crossmatch, and histocompatibility. Unfortunately, the
number of patients waiting for a deceased donor kidney in Canada increased 13% from
2001 to 2012; by the end of 2013, there were 3277 Canadians on the waiting list for a
kidney transplant.8,9

Deceased Donor Kidney Transplantation
Deceased donor kidneys come from two main sources: donors who are declared braindead or donors following a cardiac death. Historically, the deceased donor rate in Canada
has varied between 12 and 14 per million population, much lower than countries with
national donation programs, such as Spain. 42 Nonetheless, deceased donor kidneys
accounted for 61% of kidney transplants in Canada between 2004 and 2013. 9
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Compared to dialysis, deceased donor kidney transplantation substantially improves
quality of life and confers a significant long-term survival benefit (reducing the relative
risk of death by 64% at one year).5,6 Graft survival rates for patients receiving deceased
donor kidneys are 94.8% at 1 year and 82.6% at 5 years after transplant. 9

Living Donor Kidney Transplantation
Deceased donation has not met the demand for kidneys. Living kidney donation has
evolved substantially since the first kidney transplant between identical twins in 1954. 43
Beyond the developments in transplant surgery techniques and immunosuppression, there
is now a better understanding of best practices to evaluate living kidney donor candidates,
and the outcomes of living kidney donors.44
Compared to deceased donation, living kidney transplantation offers substantial benefits
to patients with ESKD, including decreased time on dialysis, and improved graft and
recipient survival.11,12 Graft survival rates for patients receiving living donor kidneys are
97.7% at 1 year and 89.2% at 5 years.9 On average, patients receiving living donor
kidneys live 10 to 15 years longer than patients on dialysis. 5
The number of living donor kidney transplants has increased by 26% between 1998 and
2008, representing about 40% of kidney transplants in Canada today. 9,10 However, the
number of living donor kidney transplants has stagnated since 2006, fluctuating between
435 and 477 donations each year.9
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Costs of Kidney Transplantation
The healthcare costs of living kidney donation are similar to or lower than costs
associated with deceased donation, and substantially lower than costs associated with
dialysis.19,45 The average cost of in-centre hemodialysis ranges from $95,000 to $107,000
per patient per year.18,19 The average initial cost for a kidney transplant approximates
$100,000 in the first year, and $20,000 in each subsequent year for follow-up and
medication costs; over 5 years, each kidney transplant results in a healthcare savings of
approximately $250,000 dollars compared to dialysis. 2,7,18,19 Phrased another way, every
100 kidney transplants result in a 5-year healthcare savings of $25 million in averted
dialysis costs.
A cost-utility analysis of renal replacement therapies demonstrates that, in the first year
compared to dialysis, transplantation results in a per-patient healthcare savings of $7119
and a net gain of 0.12 quality-adjust life-years (QALYs). Corresponding numbers in the
second-year post-transplant are savings of $43,365 and a gain of 0.11 QALYs per
patient.7

Living Kidney Donation in Canada
In Canada, there are 18 active adult kidney transplant programs across seven provinces.
Between 2004 and 2013, these centres performed 4417 living donor kidney transplants
(about 500 living kidney donor transplants a year). 9 The donors participating in these
transplants include directed donors, non-directed donors, and donors participating in
kidney paired donation. These three types of donors are described below.
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Directed donors are those who specify the recipient to whom they intend to donate their
kidney. In other words, they “direct” the donation. Directed donors may be genetically
related (such as a child or sibling) or emotionally related (such as a spouse/partner or
friend).
Non-directed donors are those who do not specify their recipient and instead donate
based on compatibility to a recipient selected from the waiting list (which may include
initiating a chain of donations through kidney paired donation). The policy of several
transplant centres is for non-directed donors to remain anonymous throughout the
donation process (i.e. they never meet their recipient).
An estimated one-third of willing directed donors are unable to proceed with donation
due to incompatibility with their intended recipient. 46 To address this, Canadian Blood
Services (CBS) established the national Kidney Paired Donation Program and the
Canadian Transplant Registry in 2009.13 Kidney paired donation (KPD) facilitates
transplantation by matching incompatible donor-recipient pairs through n-way, domino
chain, and paired exchanges.13 By 2011, all provinces with transplant programs were
fully participating. The KPD Program runs a matching algorithm against donor and
ESKD patient records in the transplant registry in four month cycles. The algorithm
identifies potential exchanges and scores matches on variables predictive of transplant
success.47 By the end of 2013, the program had facilitated 271 kidney transplants, with
the number of donations per cycle growing each year.13
Donors participating in the KPD Program face a unique set of challenges throughout their
donation process. Regulatory frameworks enacted by Health Canada necessitate donor
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travel to the recipient’s location for transplant, and as a result, 53% of these kidney paired
donors have been required to travel out-of-province for surgery. 13 This travel gives rise to
a financial burden in the form of flights and accommodations, separates donors from
loved ones at an inherently stressful time, and potentially exposes donors to language
barriers in bilingual Canada.48,49 For these reasons, CBS has emphasized the importance
of identifying barriers to program registration to ensure the long-term success of KPD in
Canada.13
The following sections serve as a critical review of living kidney donation from the
perspective of the donor, with a focus on the economic consequences of donation.

2.3.1 Medical Outcomes of Living Kidney Donors
Living kidney donation is practiced under the principle that both short-term and longterm medical risks borne by donors are outweighed by expected benefits to the recipient
and a psychological benefit of altruism to the donor.50 However, understanding and
quantifying these risks is paramount to guiding informed consent in donor registration
and facilitating donor follow-up.
The most immediate risk encountered by donors is that of surgical mortality. In a study
drawing from over 80,000 living kidney donations in the United States between 1994 and
2009, the 90-day surgical mortality was found to be 3.1 per 10,000 donors (95% CI: 2.0
to 4.6).51 Other retrospective studies in Japan and Norway found similar results. 52,53
Living kidney donors face a 25-40% reduction in glomerular filtration rate following
nephrectomy.54 There is uncertainty and debate as to whether this reduction results in
long-term adverse outcomes, such as kidney and cardiovascular disease. 55-57 Much of the
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literature on the medical risks to living kidney donors make comparisons to the general
population. However, donors are generally healthier as a group due to rigorous donation
criteria and evaluation, thus understanding the risks to donors requires comparisons to
non-donors with similar indicators of baseline good health. 21
Several studies have reported a low incidence of ESKD in living kidney donors within 10
years post-nephrectomy, ranging from 0.2% to 0.5%.58-60 However, a study in the United
States compared 96,217 donors (median follow-up of 7.6 years) to healthy matched
controls (median follow-up of 15 years) and found the cumulative incidence of ESKD
was significantly higher in the living kidney donor group (30.8 per 10,000 people, 95%
CI: 24.3 to 38.5) compared to healthy controls (3.9 cases per 10,000 people, 95% CI: 0.8
to 8.9).61 A similar study by Mjøen et al. found that living kidney donors had a hazard
ratio of 11.38 (95% CI: 4.7 to 29.63) for ESKD compared to healthy non-donors. 62
When comparing outcomes of all-cause mortality and cardiovascular disease between
living kidney donors and healthy non-donors, most studies report no differences in longterm survival or risk of developing cardiovascular disease. 51,63,64 One Norwegian study
did report significantly higher mortality in kidney donors than in matched non-donors at
25 years (adjusted HR = 1.3; 95% CI: 1.11 to 1.52), however, the accrual periods for
comparator groups differed and survival differences may reflect changes in care or
mortality trends over time.62
A Canadian retrospective study examined pregnancy outcomes post-donation. They
found that female living kidney donors who become pregnant post-donation were at a
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significantly higher risk of pre-eclampsia or gestational hypertension compared to healthy
non-donor controls (11% vs. 5%; odds ratio 2.4; 95% CI: 1.2 to 5.0). 65
No differences in risk of kidney stones requiring surgical intervention, fracture events, or
gastrointestinal bleeding have been reported across several studies which compared living
kidney donors to healthy matched non-donor controls. 66-68

2.3.2 Psychosocial Outcomes of Living Kidney Donors
Psychosocial assessments are an essential component of kidney donor evaluation,
screening, and informed consent. There is a need to identify and measure the potential
harms and benefits of living kidney donation to donor psychological well-being.
A systematic review of clinical practice guidelines for the screening and follow-up of
living kidney donors identified four major domains encompassing psychosocial
assessments: informed voluntary consent, motivation, history of mental illness or
substance abuse, and support and coping mechanisms. 69 However, the review also
reported considerable variation between guidelines and highlighted a need for highquality outcome data to guide the development of consistent and evidence-based
recommendations.69A survey of 221 transplant professionals from 40 countries noted that
living kidney donors receive inconsistent information regarding the psychosocial and
financial costs of donation during the informed consent process. 70
Clemens et al. performed a systematic review of studies capturing the post-donation
psychosocial outcomes of living kidney donors, finding 51 studies assessing 5139 donors
between 1969 and 2006.50 Only 10 of the studies followed donors prospectively to assess
psychosocial well-being, and 20 of the 41 retrospective studies did not report average
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times between donation and follow-up.50 Across reports, only 71% of eligible participants
responded, and only 29 studies compared the psychosocial health of living kidney donors
to healthy non-donor controls.50
Despite the methodological limitations of the included studies, there was overall
agreement in the literature: most donors reported either no change or an improvement in
their post-donation psychosocial well-being.50 The proportion of donors experiencing no
symptoms of depression ranged from 77% to 95% across five studies. 71-75 Furthermore, a
retrospective report by Tanrivedi et al. found that donors actually reported fewer
depressive symptoms on the Beck Depression Inventory than non-donor controls. 76
Retrospective studies by Duque et al. and Corley et al. found that 81% and 95% of living
kidney donors reported feeling happier post-donation.77,78 And across 17 studies, kidney
donors were found to have comparable or better quality of life scores compared to the
general population.50 However, not all donors experienced positive outcomes. The review
noted that some donors experienced stress due to the financial burden of donation and
some donors felt anxiety about their remaining kidney failing.50 Clemens et al. argued
that further studies with appropriate control groups were necessary to better guide donor
screening guidelines.50
To partially address these concerns, an international multi-centre cohort study
retrospectively assessed the quality of life of 203 living kidney donors compared to 104
non-donor controls.79 The researchers found that, across three distinct and validated
scales, there were no significant differences in quality of life between kidney donors and
non-donors in both unadjusted and adjusted analyses. 79 The study also reported no
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differences between donors and non-donors in number of visits to mental health
professionals or use of psychotropic medications.79
A Dutch study, which criticized previous reports for the use of inappropriate control
groups due to their retrospective nature, prospectively followed 135 living kidney donors
matched 1:1 to individuals from the general population based on gender and baseline
mental health.80 The authors found that kidney donors did not experience changes in
psychological complaints and well-being from baseline to 6 months post-donation, and
beyond this, there were no difference between donors and controls over the follow-up
period.80 The authors concluded that post-donation short-term positive or negative
variations in kidney donor psychosocial health did not differ from changes observed in a
comparable population of non-donors.80
The RELIVE Study mailed surveys to 6909 patients who donated kidneys across three
U.S. transplant centres from 1963 through to 2005. 81 The questionnaires collected
psychosocial outcomes relating to donor experience, psychological state, and relationship
with the recipient: 2455 (36%) of donors responded. 81 The authors found that 95% of
donors perceived their donation experience as positive overall, and 75% reported that
donation had positively affected the donor-recipient relationship. 81 However, the study
did caution that approximately 9% of donors reported at least one negative psychosocial
outcome, though recipient graft failure was the only significant predictor of having ≥1
poor psychosocial outcome.81
Though these recent studies of donor emotional well-being and quality of life support the
safety of living kidney donation, further large and comprehensive prospective studies are
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necessary to identify the factors associated with diminished psychosocial health and
identify donors in need of additional education or support.

2.3.3 Economic Outcomes of Living Kidney Donors
Despite the measurable health benefits to recipients and cost savings to the healthcare
system as a result of living donor kidney transplantation compared with dialysis, many
living kidney donors face economic consequences during the donation process. 14 Surveys
of donors and prospective donors have identified financial consequences to donation as
potential disincentives and a source of concern when making the decision to donate. 82,83
Understanding and quantifying the financial burden of donation on living kidney donors
is critical to guiding the informed consent process and developing reimbursement policies
that are effective and just.

Financial Burden to Donors
Clarke et al. performed a systematic review of studies reporting costs associated with
becoming a living kidney donor and found 35 studies from 12 countries that measured at
least one cost relevant to donors.15 The authors defined direct costs as those consuming
resources (travel, accommodation, medications) and indirect costs as those related to
productivity losses (lost income, dependent care, housework). This contrasts with the
prevailing view in health economic literature which characterizes direct costs as those
borne by the health sector and patients, and indirect costs as expenses which are external
to the patient and include intangible costs to society as a whole. 84 This work focuses on
the donor perspective, and as such we adopted the cost categories as defined by Clarke et
al. to permit comparisons to the existing literature. In assessing study quality, the authors
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found that 30 of the 35 studies collected cost data retrospectively, with donor recall times
ranging from 8 weeks to 9 years.15 Only four of the studies assessed the costs incurred by
donors as a primary objective, and none reported the cost definitions and criteria they
employed to estimate total costs borne by donors. 85-88
The proportion of living kidney donors incurring any costs during the donation process
ranged from 9% to 45% in 10 studies from seven countries. 72,73,85,86,89-94 A retrospective
study by Johnson et al. found that the overall costs to living kidney donors ranged from
$0 to $28,906 with an average cost of $837 (2004 USD). 73 Another retrospective study by
Smith et al. reported costs ranging from $0 to $13,788 (2004 USD).85 Unfortunately,
neither of the studies reported costs by expense type.
Donors incur out-of-pocket costs for travel and accommodation during evaluation and for
surgery, yet only four studies considered these costs explicitly. 15 One study found that
donors incurred an average of $1720 for travel and accommodation combined, with costs
ranging from $76 to $12,579 (2004 USD).87 A Canadian study reported that 53% of
donors paid for transportation and parking during the donation process. 95 A multi-centre
study in the United States found that 99% of donors experienced costs related to travel
and 88% paid for accommodation during their donation experience. 96
Indirect costs were also reported. Proportions of donors with lost earnings due to
donation ranged from 14% to 30% across three studies. 73,87,95 Only two studies collected
information on the value of income lost by donors during the donation process: a
retrospective study by Lyons et al. reported an average loss of $3386 and a prospective
study by Zuidema et al. found an average loss of $682 (2004 USD).87,88 No study
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measured the value of indirect costs due to lost household productivity, however, two
studies reported that 9-44% of donors faced costs related to caring for dependents. 95,96
Clarke et al. argued that due to the retrospective nature of the studies, lengthy timeframes
for recall, incomplete and undetailed cost data, and poor donor response rates, the
estimated costs to donors remain uncertain and likely to be underestimated in the
literature.15 The authors argued that a detailed multi-centre prospective cohort study was
necessary to comprehensively measure the costs borne by living kidney donors. 15
Since then, three prospective studies have attempted to methodically describe the costs of
donors: one in Canada and two in the United States.
Klarenbach et al. followed a group of 100 living kidney donors across seven Canadian
transplant centres between 2004 and 2008.1 They prospectively collected data on costs
and resources up to one year post-donation and comprehensively micro-costed the
economic costs (2008 CAD). The authors reported that 96% of donors incurred costs due
to donation, with 94% and 49% experiencing out-of-pocket expenses for travel and
accommodation respectively.1 Among those who incurred the expense, donors reported
an average cost of $897 (SD $1048) for ground travel, $1480 (SD $1108) for air travel,
$1759 (SD $2567) for non-hospital accommodation, and $1780 (SD $2504) for any
direct costs.1 One third of donors incurred costs >$3,000 throughout the donation
process.1 The authors reported the proportions of donors experiencing expenses, resource
consumption, and monetary value of economic consequences by cost category.
Regrettably, due to the small sample size, the study was unable to comprehensively
collect cost data for donors participating in kidney paired donation, donors with air travel
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expenses, or the burden of expenses in important donor subgroups (e.g. spousal donors
burdened with the loss of possibly two incomes). Canada is a geographically large
country where 53% of donors participating in KPD travel outside of their province to
donate; the inability to capture these important cost components of living kidney donation
is an important limitation of the cost analysis performed by Klarenbach et al.13
Two studies by Rodrigue et al. reporting findings from the Kidney Donor Outcomes
Cohort (KDOC) Study quantified costs faced by living kidney donors, the first study
restricted cost-capturing to the pre-donation period, with the second confined to a postdonation window.97,98 To quantify costs associated with donor evaluation during the predonation period, the authors recruited 194 living kidney donors (at the time of approval
for surgery) and surveys were completed an average of 7 days before surgery. 97 They
collected out-of-pocket expenses and resource use to measure evaluation-related direct
and indirect costs (USD).97 The study found that 96% of donors experienced direct costs
during the pre-donation evaluation period, with 80% of donors reporting ground travel
costs, 17% incurring costs for accommodation, and 14% facing air travel costs. For
donors reporting the expense, the mean direct cost incurred during the evaluation period
was $543 (SD $954), with the highest direct costs due to air travel (mean = $1265, SD =
$999) and accommodation (mean = $649, SD = $862). The study found that almost one
quarter of donors experienced total costs in excess of $1000 during the pre-donation
period. For the second study, the authors prospectively followed 182 living kidney donors
across six transplant centres in the United States until 12 months post-donation. 98 The
study found that 92% of donors experienced direct costs as a result of donation, with 86%
and 23% reporting expenses related to ground transportation and lodging, respectively. 98
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Among those who incurred the expense, donors reported an average cost of $388 (SD
$462) for ground travel, $1375 (SD $1440) for air travel, $1176 (SD $1582) for lodging,
and $1253 (SD $1951) for any direct costs.98 One fifth of donors reported costs
exceeding $5000, and financial burden (net financial loss divided by monthly household
income) was significantly higher with greater travel distance, lower household income,
and more unpaid work hours missed.98 The authors reported costs and resource use for
both donors and their caregivers separately by cost category. Though the largest reports
of their type, Formica et al. noted that the cohort followed by Rodrigue et al. represents
less than 3% of donations taking place in the United States during the reporting period,
and the study recruited heavily from a fairly limited geographic area in the northeast of
the country.99 Beyond this, the study did not report on the burden of costs between
important donor subgroups.
Wiseman et al. evaluated the financial burden faced by living kidney donors in a
subjective manner, arguing that though previous work had sought to quantify the costs,
little had been done to appreciate the subjective magnitude of burden imposed on donors
by these costs.100 From 2003 to 2015, the authors surveyed 1136 donors at 6 months postdonation to assess the severity of their financial burden due to donation on a scale of 0 to
10 (0 = no burden, 10 = extreme burden).100 The study found that among the 796 donors
(70%) who responded, 26% reported their financial burden as moderate (≥5), while 8%
scored their burden as ≥8.100 Interestingly, the authors found that even among those
donors who reported no direct out-of-pocket costs, almost a quarter faced considerable
financial burden.100 Beyond the degree of burden, 35% of donors used savings and 14%
borrowed money from loved ones to cover the expenses associated with donation. 100 The
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RELIVE Study, a retrospective study measuring the outcomes of living kidney donors
who donated from 1963 to 2005, found comparable results: the authors reported that 20%
of donors judged the costs they encountered during donation to be burdensome. 81
Unfortunately, the Wiseman et al. study is limited by a low response rate, a lengthy 6month recall window, and a homogenous donor sample, which potentially limits the
generalizability of their findings and underestimates the true severity of the financial
burden faced by living kidney donors.
To date, the studies by Klarenbach et al. and Rodrigue et al. offer the most
comprehensive glimpses into the costs borne by living kidney donors. However, due to
small sample sizes, limited generalizability, and incomplete cost capturing, there is an
opportunity for a large prospective cohort study to better estimate the total costs borne by
donors, to appreciate the differences in costs between donor subgroups, and to identify
factors associated with higher costs and greater financial burden among living kidney
donors.

Reimbursement Ethics and Policy
Reimbursing living kidney donors for expenses incurred during evaluation, surgery and
convalescence is justifiable and supported by a majority of transplant professionals and
by the public at large.101,102 Many have called for the need to remove financial
disincentives from living kidney donation to ensure equity, barrier free access, and
justice.103-105 The overwhelming consensus for financial neutrality in living donation
prompted the American Medical Association’s Council on Ethics and Judicial Affairs to
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support reimbursement and differentiate it from for profit donation, which is illegal in
most jurisdictions, including Canada.106
In Canada, facilitation of organ donation operates under a framework of altruism, and
provincial legislations governing donation ban the exchange of “valuable consideration”
for donated organs.107,108 However, there is considerable debate on the complex ethics of
valuable consideration and the policy prohibiting implementation of financial incentives
to increase rates of organ donation.109-113
Canadian reimbursement initiatives began in earnest with the launch of the Living Organ
Donor Expense Reimbursement Program (LODERP) in British Columbia in 2006. 114 By
the end of 2011 all seven provinces with active kidney transplant programs had initiatives
in place to reimburse donors for expenses encountered during the donation process.
These programs are administered at the provincial level and facilitated by several
organizations: Kidney Foundation of Canada (Alberta, British Columbia, Manitoba and
Saskatchewan), Trillium Gift of Life Network (Ontario), Transplant Quebec (Quebec),
and Legacy of Life (Nova Scotia).
Reimbursement administered by different organizations has resulted in marked variation
in program implementation across provinces (Table 1). Though almost all programs
provide the same total maximum amount reimbursed, the costs reimbursed by expense
type vary even between programs facilitated by the same organization . The variation in
program implementation across provinces has led many to argue for an evidence-based
national reimbursement policy with a unified strategy to reimburse donors for their
legitimate medical expenses and remove barriers to living kidney donation. 48
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Table 1. Overview and comparison of provincial reimbursement program expense ceilings by cost category
for provinces with adult kidney transplant centres
Maximum Amount Reimbursed (Per Week/Day/Night), CAD
Province

Expense Type
AB

BC

MB

NS

ON

QC

SK

Travel

$1500

$1500

$1500

$1500

$1500

$1500

$1500

Parking

$140
($20/day)

$120
($12/day)

$65

$65

$140
($20/day)

$140
($20/day)

$120
($12/day)

$625
($125/night)

$875
($125/night)

$910
($130/night)

$910
($130/night)

$625
($125/night)

$650
($130/night)

$875
($125/night)

Meals

$200
($40/day)

$175
($25/day)

$225
($25/day)

$225
($25/day)

$200
($40/day)

$225
($45/day)

$175
($25/day)

Income

$3200
($400/week)

$3200
($400/week)

$2800
($350/week)

$2800
($350/week)

$3200
($400/week)

$3200
($400/week)

$3200
($400/week)

Accommodation

0

Socioeconomic Barriers to Donation
Evidence suggests that household income is associated with access to living donor kidney
transplantation: a study reporting on 133 potential donors found that recipients with
higher incomes were more likely to receive a living donor kidney, versus a deceased
donor kidney.115 A study by Gill et al. reviewed 54,483 living donor kidney transplants
in the United States between 2000 and 2009, and found that recipients share similar
incomes to their donors.116 Thiessen et al. surveyed a small group of potential donors
who had opted out of donation and found that though the reasons for withdrawing from
donor evaluation were numerous and varied, the perceived financial burden of the
donation process was most frequently cited as the deciding factor. 117
A study by Rodrigue et al. surveyed 456 end-stage kidney disease patients (including
waitlisted transplant candidates, and recipients of both living and deceased donor
kidneys) about attitudes surrounding the financial implications of donation from a
donor’s perspective.118 Almost one-third of patients reported being told by a willing
donor candidate that they were concerned about lost income associated with the donation
process, and of those willing donor candidates who reported these concerns 64% did not
complete the donor evaluation.118 In the same study, the only significant predictor of a
willing donor candidate expressing concern for lost income was lower patient household
income.118
Another study suggests that the decline in living donation in the United States is in part
due to decrements in median household income and economic pressures negatively
influencing willingness to come forward as a living kidney donor. 119 Wiseman et al.
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found the financial burden for donors undergoing surgery during the recent economic
recession was higher than those donating pre-recession.100 Changes in living donation in
the past decade have varied between income groups: the disparity in living donation
between low-income and high-income populations has widened in response to recent
economic instability.120
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Chapter 3

3

Objectives and Hypotheses

The overarching aim of this work is to conduct a comprehensive study of the costs of
living kidney donation in Canada with the intention of describing, in detail, the costs
borne by living kidney donors and identifying differences in expenses and financial
burden between donor groups. This work will serve to inform donor reimbursement
policy and generate recommendations with the aim of removing the financial
disincentives associated with living kidney donation. The specific objectives and
hypotheses are:
Objective 1: To describe, in detail, the costs incurred by living kidney donors in Canada.
Specifically, to characterize the direct, indirect, and total costs borne by Canadian living
kidney donors throughout the transplantation process by cost category and resource type
using a micro-costing approach.
Objective 2: To identify differences in costs and financial burden between groups within
the Canadian living kidney donor population. Specifically, to identify which donors face
disproportionately higher costs, the cost categories that differ between groups, and the
factors associated with increased financial burden.
Hypothesis 1: We expect that, due to the retrospective nature and lengthy timeframes for
participant recall in previous work, the existing literature exceedingly underestimates the
true financial costs borne by donors during living kidney donation. Due to small sample
sizes, an incomplete collection of incurred costs, and a shifting landscape with the

3

introduction of Kidney Paired Donation (KPD), we expect our cost estimates to be more
accurate and, specifically, greater than those reported by Klarenbach et al. and Rodrigue
et al. previously.1,98
Hypothesis 2: We expect that, due to differences in requirements for travel and
associated flight and accommodation costs, kidney paired donors and non-directed
donors will have higher direct and total costs than other types of donors. We expect that,
due to increased costs associated with lost income, care of dependents, and lost home
productivity, living kidney donors who donate to a spouse/partner will have significantly
higher indirect and total costs than other donor-recipient relationship groups.
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Chapter 4

4

Study Design and Methods

This chapter discusses the research design and methodology common to all analyses in
the chapters that follow. It is intended to provide an overview of the methodological
approach and assumptions linking the study data and findings into a cohesive work.

Living Kidney Donor Study
The Living Kidney Donor (LKD) Study is a CIHR-funded Canadian multi-centre
prospective cohort study exploring the long-term outcomes of living kidney donation.
The LKD Study recruited living kidney donors and non-donor controls from all twelve
major transplant centres across Canada from June 2009 to December 2014
(ClinicalTrials.gov Identifier: NCT00319579). The study protocol was approved by The
University of Western Ontario Research Ethics Board for Health Sciences Research
Involving Human Subjects and all participants provided informed consent (Appendix A).
The study protocol was guided by a Pilot Phase and participants recruited into the Pilot
Phase were rolled over into Phase II of the study.
The LKD Study follows donor and control participants annually, with each participant
completing surveys, blood pressure readings, and laboratory readings for a minimum of 5
years after donation. Informed consent was obtained to perform data linkages with
healthcare record organizations and administrative databases to collect participant data
and to facilitate long-term follow up of donors and non-donor controls.
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The overarching objectives of the LKD study are to improve the practice of living kidney
donation, with an emphasis on better understanding the long-term medical risks of
donating a kidney, the psychological effects of becoming a kidney donor, and the
economic consequences incurred by living kidney donors throughout the donation
process. Given that randomization is not possible for the research objectives, the
prospective cohort design provides the highest level of epidemiological evidence
available to answer the research questions.121
The current work focuses on the financial burden involved in becoming a kidney donor
and the costs of living kidney donation up to three months post-donation. Discussion of
study methodology and the analyses in the chapters that follow are restricted to the
outcomes of non-pilot kidney donors, as the results of the Pilot Phase have been
published previously.1

4.1.1 Eligibility Criteria and Recruitment
All donors deemed eligible to donate a kidney by a nephrology team at one of the twelve
Canadian transplant centres were eligible to participate in the study. Donors were ≥18
years of age, and could speak and read in English and/or French. All participants were
enrolled in the study prior to donation. Recruiting from the twelve transplant centres,
representing all the major living kidney donor centres in Canada, helped improve study
generalizability and meet recruitment targets (Appendix B).
The specific recruitment process varied between participating transplant centres, as the
living donor evaluation process differs at each centre. Nevertheless, the recruitment
techniques across all centres included: introduction of the study to donors by members of
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the nephrology/transplant team, use of educational materials such as handouts,
identification of participants with the assistance of hospital coordinators, meeting with
donor candidates during hospital visits for their evaluation, providing donors with a study
letter of information, and obtaining informed consent.

4.1.2 Data Collection
The LKD Study schedule is divided into four data collection periods: pre-donation, perioperative period, three months post-donation, and annually post-donation (Figure 1, Part
A). The pre-donation and post-surgery data collections were coordinated by the
participant’s local transplant centre; all subsequent post-donation data collection was
completed by the central interviewing facility at the London Health Sciences Centre
(LHSC).
Following participant recruitment and informed consent, trained research staff at each
transplant centre provided donors with verbal and written instructions regarding study
participation. During this recruitment visit, participants completed case report forms
(CRF) and self-administered standardized surveys. Research staff also recorded
participant pre-donation weight, height and blood pressure, and collected urine and blood
specimens. Following surgery, local coordinators collected nephrologist, surgeon and
psychosocial consult notes, results of testing during evaluation, surgical information, and
discharge status from donor medical charts.
At three months post-donation, research staff at the central interviewing facility sent
participants the study case report forms and standardized surveys by mail. Before study
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materials were mailed, participants were contacted to remind them of an upcoming data
collection period and to verify mailing addresses.
Annually post-donation, participants are mailed a study kit containing the case report
forms and standardized surveys, a home blood pressure machine for recording
measurements, and a laboratory requisition for blood work.
Upon collection, de-identified consult notes, completed case report forms, and
standardized surveys were entered and stored in a secure online database by local and
central coordinators to ensure data quality and handling. Physical records were stored at
the central interviewing facility.

4.1.3 Retention
Loss to follow-up is a critical barrier in prospective studies and often results in bias. 122 To
minimize loss to follow-up the LKD Study employs a number of proven retention
strategies and a systematic procedure for late or missing data collection (Appendix C). 123125

Other strategies include repeated contact from both local transplant centres and the

central facility, reminder calls and letters, logos on study materials to foster a study
identity, tokens of appreciation sent alongside mailed study kits, and courier and home
nurse services (Figure 1, Part B).
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Figure 1. Data collection periods and retention strategies employed in the Living Kidney Donor Study
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4.1.4 Outcome Measurement
The scope of this work focuses solely on the economic consequences of living kidney
donation and the financial burden borne by donors to inform policies governing
reimbursement in Canada. As such, medical and psychosocial outcomes, though
important, have been omitted from our discussion of the study design and methods. The
following sections will describe the identification, collection, and measurement of
economic outcomes for living kidney donors.

Economic Outcomes
During the pilot phase, study investigators performed a systematic review of the existing
literature on the economic costs of living kidney donation. 15 Guided by this review and
through consultation with transplantation experts, a framework was developed of all costs
incurred by donors during the pre-donation, donation, and post-donation time periods
(visually represented in Figure 2). The framework defined two major types of expenses
incurred by living kidney donors: direct costs (i.e. the consumption of resources) and
indirect costs (i.e. lost productivity). This framework and detailed cost categories guided
the data collection of the economic consequences to donors.
Donor economic outcomes were measured by mailed self-administered surveys at three
months post-donation. The reasoning for this time frame is two-fold: 1) to best capture all
costs (most economic consequences are experienced by donors within 3-months postdonation) and 2) to limit recall bias (a 90-day period for self-reported information on
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costs agrees well with actual records, and recollection of costs more than twelve months
after they are incurred is likely to result in underestimates). 126,127
Detailed cost-capturing methods and the data collection tools are presented in Appendix
D.

Micro-Costing Methods
Costs incurred by donors were evaluated using the three-step micro-costing technique of
i) identification, ii) measurement, and iii) valuation of resources (Figure 2). 128

4.2.1 Resource Identification
Resources were identified through the economic outcomes framework as either direct or
indirect costs, and the unit of each resource was defined. Direct costs included expenses
for travel, accommodation, and medications. Indirect costs were associated with time and
productivity losses including: lost income, home productivity, and caring for dependents.

4.2.2 Resource Measurement
The three-month economic case report form captures direct and indirect costs borne by
donors in the form of both units of resources consumed and out-of-pocket expenses by
category. Quantifying resource utilization in each cost category by collecting the number
of units consumed (e.g. the number of nights spent in paid accommodation) allows for
portability of the results, allowing for comparisons across jurisdictions.
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Figure 2. Micro-costing mechanism applied to measure the economic consequences of living
kidney donation from the donor perspective.
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4.2.3 Resource Valuation
To describe costs, resource units were assigned a value using conventional costing
techniques and appropriate provincial or local rates and estimates (e.g. provincial ageand sex-specific average wage rates for unpaid days of work missed due to donation). For
resources where no unit cost or rate was available (e.g. expenses associated with
dependent care) donor reported out-of-pocket expenses were used instead.

4.2.4 Direct Costs
Direct costs were defined as the value of resources consumed during the pre-donation,
donation, and post-donation periods. These costs included ground and air travel costs
associated with donor evaluation, surgery and follow-up, accommodation costs during
donor evaluation and surgery, and prescription medication costs (e.g. pain medications
and antibiotics) post-donation. The direct cost for each donor was calculated as the sum
of the above-mentioned cost categories.

Ground Travel Costs
In the 3-month post-donation economic assessment, donors reported the number of
round-trips to see health professionals for living donor evaluation and the transplant
centre where these evaluations took place. The driving distance between donors’ homes
and transplant centres was calculated using Google Maps application programming
interface (API). The postal codes of donors and their respective centre were entered into
the Google Maps API which produced the shortest driving distance between the
locations. This driving distance was doubled to produce a round-trip distance-travelled,
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which was then multiplied by the reported number of round-trips to determine the
donor’s total driving distance during evaluation. The donor’s total driving distance was
then multiplied by the provincial kilometric rate for their province of residence to
estimate the total costs of ground travel (Appendix E). 129
Donors who flew to the transplant centre which they reported as the site of their
evaluations were expected to have minimal ground travel costs; and for the purposes of
this analysis had 0 kilometers inputted for their ground travel.
Donors were also asked to report the number of days and total out-of-pocket expenses for
paid parking due to ground travel for evaluation, testing, and surgery.

Air Travel Costs
In the 3-month post-donation economic assessment, donors were asked if they travelled
by airplane during the donation process. Donors who flew were asked to report the city of
departure, the city of arrival, and the number of round-trip and/or one-way flights
between these cities. Air travel rates were estimated using Google Flights between the
cities of departure and arrival for either round-trip or one-way flights. The cost of air
travel was estimated for the day of April 11, 2016, returning on April 12, 2016 (if roundtrip). Rates between cities were obtained on February 27, 2016. Rates were chosen using
Google Flights’ price graph as follows: 1) lowest available economy-class flight
regardless of time of departure or arrival, 2) direct flight, when available, and 3) use of
Air Canada (Canada’s most popular domestic airline), when available. Air travel rates
included taxes and fees.
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Air travel rates were then multiplied by the appropriate number of round-trip or one-way
flights for each donor. The total air travel cost for each donor was the sum of the cost of
flights during the donation process. Donors were also asked to report if air travel
expenses were incurred by family/friends while accompanying them during the donation
process (yes/no).

Accommodation Costs
All accommodation costs were captured in the 3-month post-donation economic
assessment.
Donors reported the number of nights spent in paid accommodation during the evaluation
and donation process. The three hotels nearest the hospital where each donor’s surgery
took place were identified using Google Maps “hotels nearby” function. Hotel rates were
chosen using the following criteria: 1) single occupancy room, 2) lowest available rate,
and 3) accommodation for the night of April 11, 2016. Rates for three hotels per hospital
were obtained on February 27, 2016. Rates were averaged across the three hotels per
hospital, and appropriate federal taxes, provincial taxes, and municipal destination
marketing fees were applied (Appendix E). The average rates (with taxes) were
multiplied by the number of nights in paid accommodation for each donor to determine
the total cost of paid accommodation.
Donors were asked to report the number of nights and total out-of-pocket expenses
related to staying with family and/or friends throughout the donation process.
Donors were asked to report the number of nights and total out-of-pocket expenses
related to staying in hospital (e.g. cable, telephone etc.) for testing and/or surgery.
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Total accommodation cost for each donor was the sum of the cost of paid
accommodation, the total out-of-pocket expenses for staying with family and/or friends,
and the total out-of-pocket expenses related to staying in hospital.

Medication Costs
In the 3-month economic assessment, donors were asked to estimate their total out-ofpocket costs for medications prescribed because of donating their kidney. Donors were
not asked to report the type or duration of prescribed medications; therefore, self-reported
out-of-pocket expenses were used as the estimate for medication costs.

4.2.5 Indirect Costs
Indirect costs were defined as the value of time sacrificed and productivity losses during
the pre-donation, donation, and post-donation periods. These costs included lost income
due to unpaid days of missed work, productivity losses associated with household and
domestic activities, and productivity losses associated with caring for dependents. The
indirect cost for each donor was calculated as the sum of the above-mentioned cost
categories.

Lost Workforce Productivity
In the 3-month economic assessment, donors were asked to report the number of days or
part days they were unable to work following donation (if they were employed) and the
number of these days that were unpaid. The number of unpaid days away from work was
multiplied by an 8-hour work-day. We then multiplied the number of hours of lost pay by
the 2016 (age-, sex-, and province-specific) average wage rates from the Labour Force
Survey to estimate lost workforce productivity due to donation (Appendix E). 130 We did
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not collect donor reported wage rates due to the invasiveness of the question and
anticipated poor response rate. The human capital approach and use of average wage
rates are suggested by the Canadian Agency for Drugs and Technologies in Health’s
guidelines for economic evaluations, have been used previously in the evaluation of the
costs incurred by living kidney donors, and are frequently used in health economic
evaluations to estimate workforce productivity.1,130,131 In accordance with Drummond et
al.’s recommendations based on equity concerns in estimating productivity losses, a
sensitivity analysis using 2016 average provincial wage rates to value lost wages was
performed: the results did not change (Appendix E).84,132

Lost Non-Workforce Productivity
All productivity losses were captured in the 3-month economic assessment. Our
assessment did not include opportunity costs.
Donors were asked to report the number of days they were unable to perform household
activities (e.g. housework, shopping etc.) and their total out-of-pocket expenses related to
these productivity losses (e.g. cost of housekeeping) even if they were fully or partially
reimbursed.
Donors were asked to report the number of days they were unable to care for dependents
(e.g. children, spouse etc.) and their total out-of-pocket expenses related to these
productivity losses (e.g. cost of a babysitter) even if they were fully or partially
reimbursed.
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4.2.6 Inflation
As donor reported out-of-pocket expenses for paid parking, staying with family and/or
friends, hospital accommodation, prescription medication, and productivity losses were
incurred by donors between the years 2009 and 2015, the total costs for these categories
were standardized to the year 2016 using inflation rates (based on Canada’s Consumer
Price Index) according to each donor’s year of surgery (Appendix E). 133 Lost wages were
estimated using the year 2016 age-, sex- and province-specific average wage rates and
ground travel was estimated using year 2016 provincial kilometric rates.

Study Characteristics
The purpose of this research is to describe the economic consequences of living kidney
donation (the financial burden borne by donors). The primary analyses are driven by data
collected during the 3-month post-donation assessment. The following section describes
power and sample size considerations, follow-up of study participants, and characteristics
of responders and non-responders.

4.3.1 Power and Sample Size
The primary outcome of the Living Kidney Donor Study is the risk of hypertension many
years after donation between donors and controls. As such, power and sample size
considerations for recruitment were calculated to detect a minimal clinically important
effect in the outcome of hypertension. However, the 95% confidence intervals for the
costing estimates do provide a plausible range of where the true parameter may lie. As
shown in the results, most cost comparisons have an upper or lower bound with no more
than a difference of $1000.
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4.3.2 Participant Recruitment and Follow-Up
During the recruitment period, a total of 1042 living kidney donors were recruited into
the study (Figure 3).
Of the 1042 donors recruited, 73 pilot donors and 57 donors who completed their
evaluation or surgery outside of Canada were excluded from our analysis, leaving 912
eligible donors.

Figure 3 LKD study participant flow diagram for donors. Excluded pilot
patient results are reported elsewhere.1 Donors missing all 3-month
economic data were included in multiple imputation analyses.
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4.3.3 Participant Characteristics
We compared donors who provided some or all 3-month economic data (responders) to
those who were missing all 3-month economic data (non-responders) across demographic
variables collected during the recruitment assessment (Table 2). Differences between
responders and non-responders were assessed using t-tests for means, Fisher’s exact tests
for proportions, and Wilcoxon rank-sum tests when the outcome distribution was skewed.
For all comparisons, p-values < 0.05 were considered statistically significant.
Table 2. Baseline characteristic of donors who partially or fully completed the 3-month
economic assessment compared to those donors missing all their 3-month data.

Baseline Characteristics

Donors reporting
3-month data
(n = 821)

Donors missing all
3-month data
(n = 91)

p-value

Age, years, mean (SD)1

47.7 (11.3)

40.9 (11.0)

<0.001

Women, n (%)

555 (68%)

54 (59%)

0.127

58.9
(18.2, 195.0)

57.2
(23.3, 221.0)

0.500

Distance from home to transplant centre where
evaluated, kilometers, median (p25, p75)
Province of transplant centre, n (%)

0.641

Alberta

115 (14%)

18 (20%)

British Columbia

251 (30%)

24 (26%)

Manitoba

32 (4%)

5 (5%)

Nova Scotia

38 (5%)

4 (4%)

Ontario

344 (42%)

35 (38%)

Quebec

41 (5%)

5 (5%)

Donation type, n (%)
Non-directed

0.039
36 (4%)

1 (1%)

Emotionally related

289 (35%)

27 (30%)

Genetically related

385 (47%)

56 (62%)

Paired

111 (14%)

7 (8%)
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Baseline Characteristics

Donors reporting
3-month data
(n = 821)

Donors missing all
3-month data
(n = 91)

Donor’s relationship to recipient, n (%)
Parent

0.131
114 (14%)

14 (15%)

68 (8%)

10 (11%)

Sibling

181 (22%)

30 (33%)

Partner/spouse

129 (16%)

9 (10%)

Friend/acquaintance

93 (11%)

11 (12%)

Other (related)

38 (5%)

4 (4%)

Other (unrelated)

51 (6%)

5 (5%)

147 (18%)

8 (9%)

Son/daughter

Don’t know the recipient who received
kidney
Marital status, n (%)

<0.001

Currently married

543 (66%)

40 (44%)

Common law/living with partner

110 (13%)

16 (18%)

Never married

91 (11%)

16 (18%)

Divorced

44 (5%)

8 (9%)

Separated

22 (3%)

9 (10%)

Widowed

11 (1%)

2 (2%)

Employment status, n (%)

<0.001

Employed full-time

518 (63%)

60 (65%)

Employed part-time

114 (14%)

9 (10%)

Homemaker

35 (4%)

4 (4%)

Student

7 (1%)

1 (1%)

Temporary sick leave or disability

17 (2%)

5 (5%)

Unemployed

29 (4%)

11 (12%)

Retired

87 (11%)

1 (1%)

Other

14 (2%)

1 (1%)

Highest level of education completed, n (%)
Primary school
Secondary school
Trade school

<0.001
15 (2%)

7 (8%)

241 (29%)

47 (52%)

53 (6%)

8 (9%)

College

215 (26%)

18 (20%)

University

297 (36%)

11 (12%)

Race, n (%)

1

0.003

White

720 (88%)

69 (76%)

Non-white

101 (12%)

22 (24%)

age at time of surgery

p-value
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There were no significant differences in between responders and non-responders on the
following baseline characteristics: proportion of women, the province where transplant
evaluation occurred, donor relationship to their recipient, and distance from home to
transplant centre.
Responders were older than non-responders (mean 47.7 vs. 40.9 years; p < 0.001) and a
higher proportion of responding donors were white (88% vs. 76%; p = 0.003). At
recruitment, responders also significantly differed from non-responders in marital status
(p < 0.001), employment status (p < 0.001), donation type (p = 0.039), and highest level
of education completed (p < 0.001).

Data Quality and Handling
The following sections describe methods used to ensure data quality and handle missing
data.

4.4.1 Data Screening and Cleaning
We systematically screened data for outlying, discrepant, and missing values to ensure
data validity, consistency, and completeness. All variables included in the micro-costing
approach were screened to ensure values fell within a plausible range. Database case
report forms were checked against physical survey records to identify potential data entry
and typographical errors (e.g. postal codes where a “0” is mistakenly inputted as “O”).
Survey skip patterns were screened (for nested questions with conditional responses) to
ensure reported values were consistent with previous answers. Multiple attempts were
made to contact donors (by phone, mail, and email) to recover any missing data via
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structured interviews and to verify discrepant values. Alternate contacts were telephoned
for updated donor contact information if information on record was no longer current.
Any remaining missing values were abstracted from nephrologist, surgeon and
psychosocial consult notes wherever possible. Statistical methods to deal with missing
data are described in detail in the following section.

4.4.2 Missing Data
Of the living kidney donors eligible for analysis of economic outcomes, 90% completed
the 3-month economic assessment (responders). Within the responder group, less than
2% of variables employed in our micro-costing approach for both direct and indirect
costs were missing. Complete-case analysis (CCA) involves the listwise deletion of cases
where any micro-costing variables are missing. CCA was available for direct costs and
indirect costs in 96% and 95% of responders, respectively. Complete-case analysis was
available for total costs (the sum of direct and indirect costs) in 93% of responders (Table
3).
Three mechanisms to missing data have been described: missing completely at random
(MCAR) in which the missingness is unrelated to the value of any variables, missing at
random (MAR) in which the missingness is dependent upon observed variables only, and
not missing at random (NMAR) in which the missing values are related to unobserved
variables.134 Missing data in our study was assumed to be missing at random. Data MAR
can be entirely accounted for by the observed variables (with complete information) and
is not associated with unobserved values. 135 As complete-case analysis may result in
biased estimates if the complete and missing cases systematically differ, multiple
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imputation (MI) was used to impute variables used in the micro-costing approach in both
the incomplete cases and in the 10% of donors missing all three-month data (nonresponders).136 Multiple imputation has been used widely in cost-effectiveness research to
impute missing or incomplete resource utilization and cost data. 137
The multiple imputation approach implemented was informed by the pattern of missing
data. Faria et al. recommends imputing at the resource level (rather than the total cost
level) when different types of resources have different patterns of missingness. 138 In light
of this recommendation, and in order to report costs and resource consumption across
groups, variables in the micro-costing approach were imputed at the disaggregate rather
than the aggregate level.138 For example, if a donor was missing the number of ground
trips to a transplant centre, we imputed this value, instead of imputing the cost of ground
travel.
Table 3. Frequency of missing variables used in micro-costing by responder group.
Missingness, n (%)
Responders
(n = 821)

Non-Responders
(n = 91)

Total
(n = 912)

Number of Trips

9 (1.1%)

91 (100%)

100 (11.0%)

Nights in Hotels

4 (0.5%)

91 (100%)

95 (10.4%)

Hospital Costs

12 (1.5%)

91 (100%)

103 (11.3%)

Friends/Family Accommodation Costs

8 (1.0%)

91 (100%)

99 (10.9%)

Parking Costs

13 (1.6%)

91 (100%)

104 (11.4%)

Medication Costs

13 (1.6%)

91 (100%)

104 (11.4%)

Days Off Without Pay

16 (1.9%)

91 (100%)

107 (11.7%)

Unable to Care for Dependents Costs

27 (3.3%)

91 (100%)

118 (12.9%)

Unable to Perform
Household Activities Costs

28 (3.4%)

91 (100%)

119 (13%)

Variable
Direct Costs

Indirect Costs
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There are two principal approaches to multivariate multiple imputation: joint modeling
and multiple imputation by chained equations (MICE).139 Joint modeling imputes all
missing values concurrently, often using a multivariate normal distribution. 139-141
Multiple imputation by chained equations is a pragmatic method to deal with missing
data occurring in several variables; the approach is based on a series of imputation
models, one for each of the imputed variables.140 There is no consensus recommendation
in the literature for choice of approach. We opted to employ MICE due to its suitability
for the missingness within our dataset and its flexibility for handling different types of
variables and distributions because each uses its own model for imputation. 142 In our
analyses, multiple imputation was performed in Stata 14.2 which allows for MICE using
the mi impute chained command.139,143
Missing binary variables (e.g. did the donor travel by plane) in our dataset were modeled
using logistic regression. Missing count variables (e.g. number of nights in paid
accommodation) were modeled using Poisson regression. Ordinal variables (e.g. severity
of post-operative complications) were modeled using ordered logit regression.
As out-of-pocket costs are non-normally distributed continuous variables (right-skewed),
we used predictive mean matching (PMM) to impute donor reported expenses (e.g. cost
of prescription medication). Predictive mean matching generates imputed values by
sampling from observed values, and as such the underlying distribution of the imputed
values matches closely with that of observed ones. 142,144 Each imputed value is randomly
drawn from the observed values of a number of “nearest neighbours” (k) with predictive
means similar to the missing observation (as determined by linear regression). 139 Based
on a simulation study, Morris et al. advocate for drawing from a pool of k = 10 donors.145
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Vroomen et al. demonstrated the validity of PMM in imputing missing cost data by
generating incomplete datasets from a complete reference dataset, imputing missing
costs, and comparing imputed values to the reference dataset. 146
We followed Stata’s guidelines in the building of imputation models; the reference
manual recommended using as many predictors as possible in the model (the
demographic and derived variables collected during the recruitment assessment),
including any cluster identifiers in the model (i.e. location of donor evaluation), and
inclusion of all variables used in later analyses (including dependent variables). 139 These
variables were complete for non-responders. Models were evaluated separately for
convergence and fit before being added to the MICE command.
White et al. argue that the number of imputations should be at least as many as the
percentage of incomplete cases (in our analysis this is ~15), while the Stata
documentation recommends generating 20 imputations to reduce sampling error. 139,142 To
be conservative, we used 20 imputations. Stata automatically combines multiply-imputed
datasets according to Rubin’s rules during analysis and when generating estimates using
the command mi estimate.147 According to Rubin’s rules, estimates are calculated for
each imputed dataset and the overall point estimate is the mean of these values, while the
standard errors are combinations of within-imputation and between-imputation
variance.147
Diagnostics of the multiply-imputed data were performed using the Stata command
midiagplots which allows for efficient comparisons of the distributions of imputed

and observed values to identify problems with the imputation model (Appendix F).
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Statistical Analyses
The following sections will describe, in detail, the statistical methods and analyses
performed in this work.
Analyses were conducted on both multiple-imputed and complete-case datasets and
estimates for each were reported (Appendix H). Descriptive statistics for incurred costs
and resource use were reported separately for i) donors who reported the outcome and ii)
all donors. Statistical tests were two-tailed using a significance level of 0.05 and analyses
were conducted using Stata Release 14.2 (StataCorp LP, College Station, TX).

4.5.1 Univariate Cost Analysis
Univariate analysis of costs incurred by living kidney donors was conducted between prespecified groups of donors to identify differences in economic outcomes. The primary
analyses compared direct, indirect, and total costs between donation-type groups: nondirected donors and kidney paired donors vs. all other donors, and relationship-type
groups (among donors not participating in non-directed or kidney paired donations):
spousal donors vs. closely-related donors (sibling, parent, child) and unrelated donors
(friends, acquaintances, other).
The distribution of cost data is generally right skewed, as costs cannot be negative and
patients with complicated cases may face substantially higher costs and use more
resources.148,149 In light of this, median costs are routinely used to describe cost data.
However, in economic evaluations, the arithmetic mean is of chief interest because of its
utility to policy and decision makers.149-151 Stata’s sktest for normality was used to
assess skewness and kurtosis of cost distributions.143 Due to the skewed nature of our cost
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data and in effort to report our findings pragmatically, incurred expenses were reported as
means (standard deviation) and medians (25th percentile, 75th percentile). Costs were
compared to the common maximum provincial reimbursement amount of $5500 and the
proportion of donors incurring costs greater than this limit was reported. Resource
consumption and counts were reported as medians (25 th to 75th percentiles).

Bootstrapping
There are several approaches to conduct univariate analyses of costs with skewed
distributions. Parametric methods such as the t-test and ANOVA are common in the
literature, however, there are no precise thresholds for the minimum sample sizes and
maximum skewness necessary to ensure the reliability of these tests. 149,152 Nonparametric tests such as the Wilcoxon rank-sum have found utility as alternatives to
parametric methods, but they merely describe differences in the cost distributions and
medians between groups and not necessarily the arithmetic mean. 149,151,153 Logarithmic
transformation of cost data has been commonly employed in healthcare cost research to
approximate normality and conduct parametric tests on transformed scales, however,
concerns about zero costs, inferences on the geometric rather than the arithmetic mean,
and retransformation with smearing factors make these methods unwieldly. 149
To compare costs between groups, we calculated arithmetic means and mean differences,
and employed non-parametric bootstrapping to build confidence intervals (CIs) for these
measures. The non-parametric bootstrap technique avoids assumptions of the distribution
and many of the problems encountered with other parametric and non-parametric tests of
costs.149 Point estimates of the arithmetic mean and mean differences are calculated
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directly from the cost data and bootstrapping provides measures of variability, including
95% confidence intervals.149 In brief, the bootstrapping approach takes repeated random
draws of the observed data (samples of the same size with replacement) and generates a
series of resamples. The statistic of interest (in our case the arithmetic mean and
difference in mean cost) can be calculated from each resample, and the distribution of
this statistic from the resamples can be used to calculate 95% confidence
intervals.149,154,155 Efron and Tibshirani recommend that at least 1000 resamples are
necessary to obtain bootstrap confidence intervals, and thus 1000 repetitions were
conducted.155,156 Bias-corrected and accelerated (BCa) bootstrap confidence intervals
perform better than standard percentile approaches and correct for skewness; we reported
the arithmetic means and mean differences of costs between groups with BC a 95%
confidence intervals.154,157,158

4.5.2 Multivariable Cost Analysis
Multivariable analysis was used to obtain adjusted comparisons of direct, indirect, and
total incurred expenses between donation-type groups and relationship-type groups.
Secondary analyses were conducted to describe the direct, indirect, and total costs
incurred by donors across sociodemographic variables, including sex, age at time of
nephrectomy (18-34 years vs. 35-54 years vs. 65+ years), distance from transplant center,
race (white vs. non-white), income, employment status (employed vs. unemployed vs.
retired vs. other), and province of transplant centre.
Trends in counts (e.g. number of visits) and skewed continuous variables (e.g. costs)
across groups were evaluated using Stata’s nptrend command: a non-parametric test for
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trends across ordered groups. The test functions as an extension of the Wilcoxon ranksum test and is intended for scenarios where a variable is measured across more than two
groups.159

Generalized Linear Models
Using multivariable models to analyze costs does not avoid the same distributional issues
of heavily skewed cost data encountered in univariate analyses. Ordinary least squares
(OLS) regressions of untransformed and transformed costs, though the most common
approaches to cost analysis, face problems with violations of the assumptions of
homoscedasticity and normally distributed error terms, and problems with
retransformation.149,152
Generalized linear models (GLM) have become increasingly used as an alternative to
OLS models to analyze costs.149 GLMs have emerged because of the flexibility they offer
in allowing mean and variance to be directly specified, and because they avoid
distributional problems in cost analysis, as mean and variance can be modelled on the
original scales.149,160 To employ GLMs in cost analysis we determine a link function and
a family based on the data. The link function describes how the mean on the original scale
is related to the linear combination of the coefficients and regressors in the model, and so
does not face issues of retransformation.149,160 The log link has been used widely in
healthcare cost literature as it predicts the log of the mean, and thus, exponentiation of the
predictions from the GLM to arrive at the arithmetic means does not require smearing
factors.149 Specification of a distributional family reflecting the mean-variance
relationship allows for heteroscedasticity to be modelled. 160 For example, the gamma
family specifies the variance as being proportional to the square of the mean. 160
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Misspecification of the link function and family may affect model fit, and result in
inefficient and biased parameter estimates.160 For our multivariable analysis, the choice
of link function was guided by the Stata program glmdiag which performs the Pregibon
linktest, Pearson’s correlation test, and the modified Hosmer-Lemeshow test. 161-163
Specification of the distributional family was informed by the modified Park test. 164
Candidate families assessed included: Gaussian (constant variance), gamma (variance
proportional to square of the mean), Poisson (variance proportional to the mean), and
inverse Gaussian (variance proportional to cube of the mean). 149 The results of model
diagnostic and goodness of fit tests are reported in Appendix G. Following these
diagnostic tests for link function and family, we employed a GLM with a log link and
gamma distribution to elicit adjusted comparisons of donor expenses between groups, a
specification commonly used in health economic literature to model costs. 160
Deviance residuals were assessed using normal plots to judge goodness of fit for our
model.160,165 The Stata program collin, which provides variance inflation factors,
tolerance, and condition index, was used to detect multicollinearity across
covariates.143,166

Average Marginal Effects
Glick et al. cautioned that, with multiplicative models such as GLM, non-linear
retransformations when estimating costs can introduce covariate imbalances. 149 To
overcome this problem, the authors recommend estimating differences between groups as
incremental costs using the technique of recycled predictions. 149 Recycled predictions
generate an identical covariate structure for each group by treating each observation as if
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they were in one group, predicting costs, and then treating each observation as if they
were in the comparison group, and again predicting the cost for each. 149,167 Differences in
the costs between individual observations reflect the marginal effect of being in the
comparison group; the average of these individual effects results in an average marginal
effect (AME) comparing costs between groups while holding all other covariates
constant.167 Stata performs recycled predictions using the margins and mimrgns
commands.143
To report the results of the multivariable analysis, we performed pairwise recycled
predictions between referent and comparator groups to calculate the adjusted AMEs (as
differences in indirect, direct, and total costs between demographic groups, donation-type
groups, and relationship-type groups), along with their 95% confidence intervals and pvalues.

Covariate Selection
The analyses were adjusted for a set of covariates identified using a theory driven
approach relying on previous literature and clinical judgement. Analyses were adjusted
for age, sex, post-operative complications, income, and transplant centre.
Age and sex are well characterized determinants of healthcare expenditures and resource
utilization.168,169 Beyond this, previous reports characterizing patient direct medical
expenses and identifying predictors of cost have adjusted for age and sex in multivariable
analyses.170,171 To be consistent with the literature we included donor sex and age at the
time of surgery as covariates in our model.
Donor complications are associated with lengthier hospital stays, a higher probability of
hospital readmission, greater use of post-discharge medications, and increased healthcare
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costs.172-174 In light of this, donor complications may result in prolonged time off work,
increased number of visits to healthcare professionals, and medication costs covered by
the donor. A study by Wiseman et al. found that operative outcomes had a significant
impact on financial burden.100 As a result, we included donors’ Clavien-Dindo
classification as a covariate in our model to adjust for post-operative complications. The
Clavien-Dindo system is a tool that ranks surgical complications based on the therapeutic
intervention necessary to correct the complication. 175 Clavien-Dindo grades were
abstracted from donor surgical notes and discharge summaries.
A report by Sanmartin et al. found that, from 1998 to 2009, out-of-pocket healthcare
expenditures increased for all Canadian households, but the increases were greater among
Canadians in the lower income quintiles.176 The authors argued that this cost burden can
result in a reduced use of healthcare services.176 Therefore, self-reported household
income of donors was included in our multivariable model.
Our prospective cohort study recruited donors from 12 transplant centres across Canada
and variations in donor selection criteria, evaluation, and follow-up cannot be ruled out.
To account for potential variation in practice patterns between centres and generate
robust standard errors that allow for intragroup correlation, we specified the transplant
centre of donor evaluation as the cluster variable used in Stata’s variance estimator for
multivariable analyses.143

STROBE Statement and Checklist
This work, including its reporting, adheres to the recommendations of the STrengthening
the Reporting of OBservational studies in Epidemiology (STROBE) initiative, statement
and checklist for cohort studies. (Appendix I).177
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Chapter 5

5

Results
Descriptive Statistics

This section reports the demographic characteristics and economic outcomes of our
cohort of Canadian living kidney donors. Specifically, it describes the direct, indirect, and
total costs incurred and resources consumed by donors throughout the living donation
process by cost category and resource type. Differences in demographic characteristics
between groups were assessed using analysis of variance for means, and Fisher’s exact
tests for proportions. For all comparisons, p-values < 0.05 were considered statistically
significant.

5.1.1 Demographic Characteristics
The demographic characteristics of study participants are presented in Table 4. Most
living kidney donors enrolled in the study (n = 912) were recruited at transplant centres in
two provinces: British Columbia (30%) and Ontario (42%). The average age at the time
of donation was 47.0 years, and most donors were women (67%) and white (87%).
Donors underwent transplant surgery between 2009 and 2015, and at the time of surgery,
64% were married, 77% were employed, and 60% lived less than 100 km from their
transplant centre. Most donors had completed university as their highest level of
education (34%), followed closely by secondary school (32%) and college (26%).
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Among the 668 donors reporting income, 35% had an annual household income greater
than $100,000 (CAD). In relation to their recipients, donors were most commonly
siblings (23%), followed by spouses/partners (15%), parents (14%), friends (11%), and
sons/daughters (9%) of their recipients. In total, 17% of all donors participated in either
kidney paired (13%) or non-directed (4%) donations, and as such did not know the
recipient who received their kidney.

Donation-Type Groups
Donor characteristics were generally similar across donation-type groups; exceptions
include differences in racial makeup (proportion of white donors: non-directed = 100%
vs. kidney paired = 86% vs. all others = 85%, p = 0.02) and age: kidney paired donors
were significantly older than all other donors at the time of surgery (49.9 years vs. 46.5
years, p = 0.01).

Relationship-Type Groups
Although donors across relationship-type groups were mostly similar with respect to
demographic characteristics, there were significant differences across the three groups in
the proportion of female donors (spousal = 81% vs. closely related = 63% vs. unrelated =
66%, p < 0.001) and in donor racial makeup (proportion of white donors: spousal = 88%
vs. closely related = 82% vs. unrelated = 92%, p = 0.004). Additionally, at the time of
surgery, spousal donors were significantly older than both closely related and unrelated
donor groups (49.6 years vs. 46.0 years and 45.4 years respectively, p = 0.001).
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Table 4. Demographic characteristics of living kidney donors.
Donation-type group
(N = 912)
Variable

Relationship-type group
(N = 757)2

All donors
(N = 912)

Non-directed donors
(n = 37)

Kidney paired
donors
(n = 118)

All other donors
(n = 757)

Spousal donors
(n = 138)

Closely related
donors
(n = 417)

Unrelated donors
(n = 202)

Age at donation, years, mean
(SD)

47.0 (11.5)

47.6 (12.9)

49.9 (10.7)

46.5 (11.4)

49.6 (10.7)

46.0 (11.9)

45.4 (10.6)

Female, n (%)

609 (67%)

24 (65%)

78 (66%)

507 (67%)

112 (81%)

261 (63%)

134 (66%)

789 (87%)

37 (100%)

101 (86%)

651 (86%)

121 (88%)

344 (82%)

186 (92%)

3 (0%)
132 (14%)
180 (20%)
209 (23%)
222 (24%)
165 (18%)
1 (0%)

0 (0%)
3 (8%)
5 (14%)
8 (22%)
11 (30%)
10 (27%)
0 (0%)

0 (0%)
10 (9%)
15 (13%)
21 (18%)
45 (38%)
27 (23%)
0 (0%)

3 (0%)
119 (16%)
160 (21%)
180 (24%)
166 (22%)
128 (17%)
1 (0%)

1 (1%)
20 (14%)
26 (19%)
31 (22%)
32 (23%)
28 (20%)
0 (0%)

0 (0%)
72 (17%)
85 (20%)
103 (25%)
91 (22%)
65 (16%)
1 (0%)

2 (1%)
27 (13%)
49 (24%)
46 (23%)
43 (21%)
35 (17%)
0 (0%)

583 (64%)

20 (54%)

86 (73%)

477 (63%)

120 (87%)

249 (60%)

108 (53%)

126 (14%)

7 (19%)

17 (14%)

102 (13%)

18 (13%)

52 (12%)

32 (16%)

83 (9%)
107 (12%)
13 (1%)

4 (11%)
6 (16%)
0 (0%)

6 (5%)
8 (7%)
1 (1%)

73 (10%)
93 (12%)
12 (2%)

0 (0%)
0 (0%)
0 (0%)

42 (10%)
65 (16%)
9 (2%)

31 (15%)
28 (14%)
3 (1%)

546 (60%)

21 (57%)

67 (57%)

458 (61%)

85 (62%)

255 (61%)

118 (58%)

Race, n (%)
White
Year of surgery, n (%)
2009
2010
2011
2012
2013
2014
2015
Marital status, n (%)
Married
Common-law/living with
partner
Separated or divorced
Never married
Widowed
Donor evaluation <100 km of
home, n (%)
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Donation-type group
(N = 912)
Variable

Relationship-type group
(N = 757)2

All donors
(N = 912)

Non-directed donors
(n = 37)

Kidney paired
donors
(n = 118)

All other donors
(n = 757)

Spousal donors
(n = 138)

Closely related
donors
(n = 417)

Unrelated donors
(n = 202)

578 (63%)
123 (13%)
87 (10%)
124 (14%)

18 (49%)
10 (27%)
2 (5%)
7 (19%)

79 (67%)
16 (14%)
13 (11%)
20 (17%)

481 (64%)
123 (13%)
72 (10%)
107 (14%)

70 (51%)
25 (18%)
21 (15%)
22 (16%)

275 (66%)
46 (11%)
38 (9%)
58 (14%)

136 (67%)
26 (13%)
13 (6%)
27 (13%)

Employment status, n (%)
Employed (full-time)
Employed (part-time)
Retired
Other
Education level, n (%)
Primary School
Secondary school
Trade school
College
University
Annual household income, n
(%)1
<$10,000
$10,000 to $20,000
$20,000 to $30,000
$30,000 to $40,000
$40,000 to $50,000
$50,000 to $60,000
$60,000 to $70,000
$70,000 to $80,000
$80,000 to $90,000
$90,000 to $100,000
>$100,000

22 (2%)
288 (32%)
61 (7%)
233 (26%)
308 (34%)

0 (0%)
10 (27%)
1 (3%)
8 (22%)
18 (49%)

3 (3%)
27 (23%)
8 (7%)
30 (25%)
40 (42%)

19 (3%)
251 (33%)
52 (7%)
195 (26%)
240 (32%)

3 (2%)
41 (30%)
12 (9%)
41 (30%)
41 (30%)

11 (3%)
139 (33%)
25 (6%)
101 (24%)
141 (34%)

5 (2%)
71 (35%)
15 (7%)
53 (26%)
58 (29%)

11 of 668 (2%)
26 of 668 (4%)
35 of 668 (5%)
46 of 668 (7%)
42 of 668 (6%)
40 of 668 (6%)
65 of 668 (10%)
60 of 668 (9%)
57 of 668 (9%)
51 of 668 (8%)
235 of 668 (35%)

2 of 29 (7%)
2 of 29 (7%)
3 of 29 (10%)
3 of 29 (10%)
3 of 29 (10%)
2 of 29 (7%)
2 of 29 (7%)
1 of 29 (3%)
2 of 29 (7%)
1 of 29 (3%)
8 of 29 (28%)

1 of 96 (1%)
3 of 96 (3%)
7 of 96 (7%)
2 of 96 (2%)
2 of 96 (2%)
8 of 96 (8%)
6 of 96 (6%)
15 of 96 (16%)
6 of 96 (6%)
5 of 96 (5%)
41 of 96 (43%)

8 of 543 (1%)
21 of 543 (4%)
25 of 543 (5%)
41 of 543 (8%)
37 of 543 (7%)
30 of 543 (6%)
57 of 543 (11%)
44 of 543 (8%)
49 of 543 (9%)
45 of 543 (8%)
186 of 543 (34%)

1 of 96 (1%)
3 of 96 (3%)
6 of 96 (6%)
11 of 96 (11%)
7 of 96 (7%)
6 of 96 (6%)
12 of 96 (13%)
6 of 96 (6%)
8 of 96 (8%)
8 of 96 (8%)
28 of 96 (29%)

4 of 296 (1%)
11 of 296 (4%)
11 of 296 (94%)
21 of 296 (7%)
20 of 296 (7%)
16 of 296 (5%)
31 of 296 (10%)
26 of 296 (9%)
29 of 296 (10%)
24 of 296 (8%)
103 of 296 (35%)

3 of 151 (2%)
7 of 151 (5%)
8 of 151 (5%)
9 of 151 (6%)
10 of 151 (7%)
8 of 151 (5.3%)
14 of 151 (9%)
12 of 151 (8%)
12 of 151 (8%)
13 of 151 (9%)
55 of 151 (36%)

Annual household income,
median (IQR), (CAD 2016)3

$81,659
(48,449-114,730)

$62,271
(36,253- 105,937)

$91,598
(63,127-114,730)

$76,607
(47,580-113,047)

$82,608
(50,923-114,532)

$85,203
(47,688-114,730)

$81,376
(47,867-114,631)
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Donation-type group
(N = 912)
Variable

Relationship-type group
(N = 757)2

All donors
(N = 912)

Non-directed donors
(n = 37)

Kidney paired
donors
(n = 118)

All other donors
(n = 757)

Spousal donors
(n = 138)

Closely related
donors
(n = 417)

Unrelated donors
(n = 202)

Province of transplant centre,
n (%)
Alberta
British Columbia
Manitoba
Nova Scotia
Ontario
Quebec

132 (15%)
274 (30%)
37 (4%)
42 (5%)
379 (42%)
46 (5%)

5 (14%)
13 (35%)
0 (0%)
1 (3%)
18 (48%)
0 (0%)

14 (12%)
47 (48%)
2 (2%)
4 (3%)
38 (32%)
3 (3%)

115 (15%)
204 (27%)
35 (5%)
37 (5%)
323 (43%)
43 (6%)

10 (7%)
41 (30%)
2 (1%)
4 (3%)
67 (49%)
14 (10%)

70 (17%)
106 (25%)
27 (6%)
27 (6%)
164 (39%)
23 (6%)

35 (17%)
57 (28%)
6 (3%)
6 (3%)
92 (46%)
6 (3%)

Relationship to recipient, n
(%)
Sibling
Parent
Son/daughter
Spouse/partner
Friend
Don’t know recipient
Other

211 (23%)
128 (14%)
78 (9%)
138 (15%)
104 (11%)
155 (17%)
98 (11%)

0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
37 (100%)
0 (0%)

0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
118 (100%)
0 (0%)

211 (28%)
128 (17%)
78 (10%)
138 (18%)
104 (14%)
0 (%)
98 (13%)

0 (0%)
0 (0%)
0 (0%)
138 (100%)
0 (0%)
0 (0%)
0 (0%)

211 (51%)
128 (31%)
78 (19%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)

0 (0%)
0 (0%)
0 (0%)
0 (0%)
104 (51%)
0 (0%)
98 (49%)

1

Annual household income was an optional response and thus only available for 668 donors. Responses for all other variables were complete.
Among donors not participating in non-directed or kidney paired donations.
3 Median (IQR) income available from all donors: derived from mid-point of imputed categorical values inflated to 2016 Canadian dollars (i.e. $15,000 when the donor reported
an income level of $10,000 to $20,000). An income of $110,000 was used for donors reporting household incomes >$100,000, and $5000 was used for donors reporting
<$10,000.
2

38

5.1.2 Costs Incurred and Resources Consumed
All costs are reported in 2016 Canadian dollars (CAD) as means (standard deviation)
and medians (25th percentile-75th percentile).
For all donors, the mean total cost (sum of direct and indirect costs) was $4790 (6122),
and median total cost was $2616 (1073-6120). The mean direct cost incurred (from the
beginning of donor evaluation up to three months post-donation) was $2110 (2505), and
the median direct cost was $1302 (581-2674) (Table 5). The mean indirect cost incurred
by all donors was $2679 (5478), and median indirect cost was $22 (0-2770).
Table 5. Direct, indirect, and total incurred costs
(CAD), for all donors, including those incurring no
expenses (n = 912).
Costs incurred, all donors (CAD)
Cost type
Mean (SD)

Median (25th-75th percentile)

Direct

2110 (2505)

1302 (581-2674)

Indirect

2679 (5478)

22 (0-2770)

Total

4790 (6122)

2616 (1073-6120)

Approximately 23% of living kidney donors incurred less than $1000 in total costs
throughout the donation process (Figure 4). However, about 28% of donors experienced
costs >$5500, which is the most common maximum amount of reimbursement offered
by provincial programs. Beyond this, 13.3% of donors experienced total costs over
$10,000 and 8.6% of donors incurred total costs greater than 25% of their household
income.
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Figure 4. Relative frequency of total costs incurred by living kidney donors (n = 912).

Direct Costs and Resources
Among donors incurring direct costs, the greatest cost was for ground travel, followed
by non-hospital paid accommodation (Table 6). Incurred expenses most frequently
reported by donors were for ground travel (90%), parking (90%), and medications
(77%).
Donors reported a median of 10 return trips to transplant centres to see health
professionals. Air travel was reported by 21% of donors with a median of 1 return flight.
Among donors reporting air travel, 71% had friends and/or family who incurred flight
costs while accompanying them throughout the donation process. Approximately 45%
of donors reported costs for non-hospital paid accommodation, and stayed a median of 4
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nights. Additionally, 38% of donors reported that friends and/or family incurred
accommodation costs while accompanying them during their kidney donation.
Among those reporting the outcome or consuming the resource, the mean costs per
donor were $1113 for ground travel, $1063 for non-hospital paid accommodation, $781
for accommodation with family or friends, $294 for hospital accommodation, $138 for
parking, and $69 for pain medications or antibiotics post-surgery. For donors who flew
during the evaluation and donation process, the average cost of air travel was $639.
For all donors (including those reporting no out-of-pocket expenses for any cost
category), the average costs per donor were $999 for ground travel, $474 for nonhospital paid accommodation, $203 for accommodation with family or friends, $137 for
air travel, $133 for hospital accommodation, $122 for parking, and $43 for medications.

41

Table 6. Direct costs (2016 CAD) incurred and resource use from 3-month economic assessment.

Cost category

Travel

Accommodation

Medication

Resource use3

Costs for donors reporting expense
(CAD)

Costs for all donors, n = 912
(CAD)

Donors
reporting
resource,
n (%)2

Units

Median
(IQR)

Average (SD)

Median
(IQR)

Average (SD)

Median (IQR)

Ground travel

818 (90%)

# Return trips

10 (7-15)

1113 (1623)

513 (194-1261)

999 (1574)

407 (129-1146)

Air travel

195 (21%)

# Return trips

1 (1-2)

639 (462)

561 (327-757)

137 (338)

0 (0-0)

Parking1

824 (90%)

# Days of
paid parking

7 (4-11)

138 (292)

104 (55-165)

122 (278)

90 (42-158)

Family and
friends1

287 (31%)

# Nights

6 (3-12)

781 (1497)

319 (160-774)

203 (835)

0 (0-42)

Non-hospital
paid

407 (45%)

# Nights

4 (2-8)

1063 (1711)

618 (227-1249)

474 (1258)

0 (0-540)

Hospital1

414 (45%)

# Nights

4 (3-5)

294 (522)

105 (48-341)

133 (381)

0 (0-101)

Post-donation
pain medication
or antibiotics
after hospital
discharge1

700 (77%)

Drugs taken
(yes/no)

n/a

69 (211)

33 (21-63)

43 (170)

16 (0-45)

Description

1

Self-reported costs (not micro- costed).
Number of donors reporting resource use (even if no out-of-pocket expenses were incurred).
3 In donors reporting the outcome; medications provided in hospital are covered through universal health care. Some outpatient drugs are also covered through universal healthcare
2

plans for segments of the population (e.g. in the province of Ontario, Canada those 65 years and older have universal drug benefits).
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Indirect Costs and Resources
Across all donors, 707 (78%) reported that they were unable to go to work for a median
of 35 days following surgery (Table 7). Lost income for donors who were unable to
work, including time off with or without loss of pay (i.e. use of sick days or vacation
time), was an average of $8702 per donor. Moreover, 39% of all donors reported that
time away from work resulted in lost wages, with a median of 20 days unpaid. Among
donors who reported unpaid time off work, the average loss of wages was $6322 per
donor.
Across all donors, 740 (81%) were unable to perform household activities for a median of
15 days post-surgery, and 516 (57%) were unable to care for dependents for a median of
14 days post-surgery. Among donors reporting productivity losses, household and
dependent out-of-pocket costs incurred were an average of $736 and $977 per donor,
respectively.
For all 912 donors (including those reporting no productivity losses), the mean costs per
donor were $6762 for inability to work, $2470 for lost wages, $112 for lost household
productivity, and $97 for caring for dependents.
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Table 7. Indirect costs (2016 CAD) incurred and resource use, up to 3-month economic assessment.

Cost category

Lost income*

Lost productivity

* Time

Costs for donors reporting expense
(CAD)

Number of days5
Median (IQR)

Average (SD)

Median (IQR)

Average
(SD)

Median (IQR)

Unable to work if
employed1

707 (78%)

35 (15-60)

8702 (6709)

7488 (3391-12,447)

6762 (6935)

5572 (597-11,119)

Unpaid time off
work2

356 (39%)

20 (9-42)

6322 (6779)

4055 (1881-8956)

2470 (5239)

0 (0-2579)

Unable to perform
household activities3

740 (81%)

15 (10-30)

736 (2881)

320 (204-531)

112 (1149)

0 (0-0)

Unable to care for
dependants3

516 (57%)

14 (7-25)

977 (2159)

344 (172-657)

97 (740)

0 (0-0)

Description

valued at provincial average wage rate: assuming 8-hour work day
With or without loss of pay.
2 Included in calculation of total cost.
3 Self-reported costs (not micro-costed).
4 Number of donors reporting resource use (even if no out-of-pocket expenses were incurred).
5 In donors reporting the outcome.
1

Costs for all donors, n = 912
(CAD)

Donors
reporting
resource,
n (%)4
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Univariate Analysis of Costs
This section describes differences in direct, indirect, and total costs borne by donors
contrasting donation-type and relationship-type groups within the Canadian living kidney
donor population. Costs are reported in 2016 Canadian dollars as means and mean
differences with 95% confidence intervals.

5.2.1 Costs Incurred by Donation-Type Groups
For the period beginning with donor evaluation and ending at 3 months post-surgery,
non-directed donors (n = 37) incurred average direct, indirect, and total costs of $2095,
$2550, and $4645, respectively (Table 8). Kidney paired donors (n = 118) incurred
average direct, indirect, and total costs of $2394, $2045, and $4439, respectively. The
mean direct, indirect, and total expenses incurred by all other donors (n = 757) were
$2067, $2785, and $4852, respectively.
There were no significant differences in the mean direct, indirect, and total costs incurred
by either non-directed donors or kidney paired donors, as compared to all other donors.
The mean differences in total costs experienced by non-directed donors and kidney
paired donors relative to the total costs incurred by all other donors were -$207 (-2167 to
1753) and -$413 (-1537 to 712), respectively (Figure 5). For non-directed donors, the
mean differences in direct and indirect costs incurred compared to all other donors were
$28 (804 to 859) and -$235 (-1482 to 1951), respectively. For kidney paired donors, the
mean differences in direct and indirect costs relative to all other donors were $327 (-237
to 890) and -$740 (-1595 to 116), respectively.
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Table 8. Unadjusted direct, indirect, and total costs (2016 CAD) incurred by living kidney donors, by donation-type group (n = 912).
All Other Donors

Non-Directed Donors

Kidney Paired Donors

All Other
Donors

Non-Directed
Donors

Kidney
Paired
Donors

Mean
(95% CI)1

MD
(95% CI)2

Mean
(95% CI)1

MD
(95% CI)2

Mean
(95% CI)1

MD
(95% CI)2

Median
(IQR)

Median
(IQR)

Median
(IQR)

Direct

2067
(1879 to 2255)

ref

2095
(1266 to 2923)

28
(-804 to 859)

2394
(2040 to 2748)

327
(-237 to 890)

1221
(551-2550)

1984
(702-2639)

2060
(1022-3263)

Indirect

2785
(2372 to 3197)

ref

2550
(810 to 4290)

-235
(-1482 to 1951)

2045
(1366 to 2724)

-740
(-1595 to 116)

40
(0-2832)

104
(0-2499)

3
(0-2359)

Total

4852
(4396 to 5307)

ref

4645
-207
(2694 to 6595) (-2167 to 1753)

4439
(3607 to 5271)

-413
(-1537 to 712)

2520
(1016-6230)

2695
(1191-4477)

2970
(1639-5933)

Cost type

1 Bootstrapped
2

mean and 95% confidence interval.
MD = mean difference, as marginal effect from univariate generalized linear model.

Figure 5. Mean direct and indirect costs by cost category and donation-type group.
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5.2.2 Costs Incurred by Relationship-Type Groups
As of three months post-donation, spousal donors (n = 138) incurred average direct,
indirect, and total costs of $2379, $2947, and $5326, respectively (Table 9). Closely
related donors (n = 417) incurred average direct, indirect, and total costs of $1984,
$2963, and $4947, respectively. And finally, the mean direct, indirect, and total expenses
incurred by unrelated donors (n = 202) were $2026, $2305, and $4330, respectively.
There were no significant differences in the mean direct, indirect, and total costs incurred
by either closely related donors or unrelated donors, as compared to spousal donors. For
closely related donors, the mean difference in total costs relative to spousal donors was $379 (-1693 to 935). For unrelated donors, the mean difference in total costs compared to
spousal donors was -$996 (-2393 to 402).
The mean differences in direct costs incurred by closely related donors and unrelated
donors compared to those incurred by spousal donors were -$395 (-943 to 153) and $353 (-955 to 249), respectively (Figure 6). Mean differences in indirect costs compared
to spousal donors were $16 (-1146 to 1178) for closely related donors, and -$642 (-1842
to 557) for unrelated donors.
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Table 9. Unadjusted direct, indirect, and total costs (2016 CAD) incurred by living kidney donors, by relationship-type group (n = 757)3.
Spousal Donors
Cost type
Direct
Indirect
Total

Closely Related Donors

Unrelated Donors

Spousal
Donors

Closely
Related
Donors

Unrelated
Donors

Mean
(95% CI)1

MD
(95% CI)2

Mean
(95% CI)1

MD
(95% CI)2

Mean
(95% CI)1

MD
(95% CI)2

Median
(IQR)

Median
(IQR)

Median
(IQR)

2379
(1815 to 2943)

ref

1984
(1750 to 2217)

-395
(-943 to 153)

2026
(1670 to 2381)

-353
(-955 to 249)

1289
(562-2471)

1193
(554-2574)

1214
(509-2473)

2963
(2423 to 3503)
4947
(4350 to 5544)

16
(-1146 to 1178)
-379
(-1693 to 935)

2305
(1669 to 2941)
4330
(3593 to 5068)

-642
(-1842 to 557)
-996
(-2393 to 402)

139
(0-3034)
2190
(1097-6480)

25
(0-2931)
2629
(963-6159)

15
(0-2668)
2493
(1043-6204)

2947
(1751 to 4143)
5326
(3985 to 6667)

ref
ref

1 Bootstrapped

mean and 95% confidence interval.
MD = mean difference, as marginal effect from univariate generalized linear model.
3 Among donors not participating in non-directed or kidney paired donations.
2

Figure 6. Mean direct and indirect costs by cost category and relationship-type group.
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Multivariable Analyses of Costs
This section describes the adjusted average marginal effects of donation-type,
relationship-type, and demographic characteristics on mean direct, indirect, and total
costs incurred by living kidney donors during the donation process. Marginal effects are
reported as mean differences and 95% confidence intervals in costs (in 2016 Canadian
dollars) compared to a reference category. Average marginal costs are adjusted for age,
sex, income level, Clavien-Dindo grade, and transplant centre.

5.3.1 Primary Analysis
In adjusted analyses, the mean direct costs experienced by either non-directed donors or
kidney paired donors were not significantly different compared to the direct costs
incurred by all other donors (Table 10). The mean differences in direct costs borne by
non-directed donors and kidney paired donors relative to all other donors were $119 (644 to 882) and $321 (-54 to 695), respectively. Adjusted mean indirect and total costs
incurred by either non-directed donors or kidney paired donors were not significantly
different than those experienced by all other donors. Mean differences in indirect and
total costs, compared to all other donors, were respectively -$351 (-1742 to 1040) and $434 (-1632 to 765) for non-directed donors. For kidney paired donors, mean differences
in indirect and total costs relative to all other donors were -$252 (-958 to 453) and $120
(-786 to 1026), respectively.
The mean indirect out-of-pocket expenses incurred by spousal donors were not
significantly different compared to either closely related donors or unrelated donors. In
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adjusted analyses, mean differences in indirect costs experienced by closely related
donors and unrelated donors relative to spousal donors were $50 (-1243 to 1343) and $856 (-1834 to 122), respectively. Mean differences in direct and total costs incurred by
closely related donors and unrelated donors compared to the referent group of spousal
donors were not significant. Mean differences in direct and total costs, compared to
spousal donors, were respectively -$235 (-660 to 190) and -$332 (-1565 to 901) for
closely related donors. For unrelated donors, mean differences in direct and total costs
relative to spousal donors were -$122 (-851 to 606) and -$1034 (-2136 to 67),
respectively.

5.3.2 Secondary Analyses
In adjusted analyses, donors who lived further from the transplant centre in which they
were evaluated (≥100 km) experienced significantly higher direct and total costs, as
compared to donors who lived closer (<100 km); mean differences in indirect costs
between these two groups was non-significant.
Though older and younger donors did not significantly differ in total costs incurred, there
were significant differences in indirect and direct costs between the groups (Figure 7). In
multivariable analyses, donors in the 35 to 54 year-old and 55+ year-old age groups
experienced significantly higher mean direct costs compared to the referent 18 to 34
year-old donor group (Table 10). Donors 55 years of age and older faced significantly
lower mean indirect costs compared to 18 to 34 year-old donors (mean difference = $1543 [-2622 to -465], p = 0.005). The mean differences in total costs compared to 18 to
24 year-old donors were not significant for any age group.
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There was a significant trend of an increasing number of trips to transplant centres for
evaluation (p = 0.03) and higher travel costs (p < 0.001), as well as greater number of
nights in paid accommodation (p <0.001) and higher accommodation costs across older
age groups (p = 0.004). Conversely, the number of days off work (p <0.001) and lost
wages significantly decreased across older age groups (p <0.001).

Figure 7. The mean direct and indirect costs incurred by donors by age category.

In adjusted analyses, the mean costs incurred by male donors and female donors did not
differ significantly; mean differences in direct and indirect costs for female donors
relative to male donors were -$75 (-381 to 231) and -$506 (-152 to 1164), respectively.
The indirect and total costs experienced by employed donors were significantly higher
than both unemployed donors and retired donors. Mean differences in indirect and total
costs incurred, compared to employed donors, were respectively -$1838 (-2580 to -1096,
p < 0.001) and -$2433 (-3369 to -1497, p <0.001) for unemployed donors, and -$2614 (3214 to -2014, p < 0.001) and -$2482 (-3262 to -1702, p < 0.001) for retired donors.
Compared to donor households making less than $20,000 in annual income, the average

51

marginal effect of household income (across all levels of income ≥$20,000) on donor
direct, indirect, and total costs was non-significant.
Compared to those donating in Ontario, donors who donated their kidneys in Alberta and
Manitoba experienced significantly lower mean direct costs. Mean differences in direct
expenses compared to Ontarian donors were -$594 (-1001 to -187, p = 0.004) in Alberta
and -$1032 (-1711 to -354, p = 0.003) in Manitoba. Indirect and total costs of donating in
any province did not differ significantly compared to donating in Ontario.
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Table 10. Adjusted1 average marginal effects of demographic variables on direct, indirect, and total
costs (2016 CAD) incurred by living kidney donors (n = 912).
Direct costs (CAD)

Indirect costs (CAD)

Total costs (CAD)

Variable
Marginal effect
(95% CI)

p

Marginal effect
(95% CI)

p

Marginal effect
(95% CI)

p

Donation-type
All other donors

ref

ref

ref

Non-directed donors

119 (-644 to 882)

0.76

-351 (-1742 to 1040)

0.62

-434 (-1632 to 765)

0.48

Kidney paired donors

321 (-54 to 695)

0.09

-252 (-958 to 453)

0.48

120 (-786 to 1026)

0.80

Relationship-type2
Spousal donors

ref

ref

ref

Closely related donors

-235 (-660 to 190)

0.28

50 (-1243 to 1343)

0.94

-332 (-1565 to 901)

0.60

Unrelated donors

-122 (-851 to 606)

0.74

-856 (-1834 to 122)

0.09

-1034 (-2136 to 67)

0.07

<0.001

-235 (-896 to 425)

0.49

2583 (1813 to 3353)

0.63

-506 (-152 to 1164)

0.13

-566 (-10 to 1142)

Distance from centre
<100 km

ref

≥100 km

2645 (2229 to 3060)

ref

ref
<0.001

Sex
Male
Female

ref
-75 (-381 to 231)

ref

ref
0.054

Age (years)
<35

ref

ref

ref

35 to 54

570 (115 to 1025)

0.01

-762 (-1939 to 415)

0.20

-70 (-1392 to 1252)

0.92

55+

712 (141 to 1283)

0.01

-1543 (-2622 to -465)

0.005

-597 (-1786 to 593)

0.33

Race
White
Non-White

ref
-234 (-673 to 205)

ref
0.30

-390 (-1553 to 772)

ref
0.51

-403 (-1641 to 835)

0.52
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Direct costs (CAD)

Indirect costs (CAD)

Total costs (CAD)

Variable
Marginal effect
(95% CI)

p

Marginal effect
(95% CI)

p

Marginal effect
(95% CI)

p

Income (CAD)
<$20,000

ref

ref

ref

$20,000 to $40,000

759 (-144 to 1663)

0.10

617 (-1990 to 3224)

0.64

1569 (-1099 to 4237)

0.25

$40,000 to $60,000

742 (-129 to 1613)

0.09

-915 (-3070 to 1241)

0.40

14 (-2217 to 2244)

0.99

$60,000 to $80,000

752 (-113 to 1618)

0.09

-585 (-3048 to 1877)

0.64

329 (-2038 to 2697)

0.79

$80,000 to $100,000

319 (-502 to 1141)

0.44

-1544 (-4050 to 961)

0.23

-993 (-3625 to 1639)

0.46

>$100,000

346 (-481 to 1173)

0.41

-1894 (-4011 to 223)

0.08

-1391 (-3451 to 669)

0.18

Employment status
Employed

ref

ref

ref

Unemployed

-551 (-1114 to 11)

0.06

-1838 (-2580 to -1096)

<0.001 -2433 (-3369 to -1497) <0.001

Retired

-190 (-542 to 162)

0.29

-2614 (-3214 to -2014)

<0.001 -2482 (-3262 to -1702) <0.001

Other

112 (-706 to 931)

0.79

-204 (-2054 to 1646)

0.83

-218 (-2178 to 1742)

0.83

Province of transplant
centre
Ontario

ref

Alberta

-594 (-1001 to -187)

0.004

764 (-586 to 2114)

0.27

212 (-1086 to 1510)

0.75

77 (-317 to 471)

0.70

-45 (-911 to 820)

0.92

177 (-747 to 1100)

0.71

British Columbia
Manitoba

ref

-1032 (-1711 to -354)

0.003

480 (-1652 to 2612)

0.66

-355 (-2407 to 1698)

0.74

Nova Scotia

312 (-454 to 1078)

0.42

-405 (-1997 to 1187)

0.62

0 (-1740 to 1739)

1.00

Quebec

106 (-743 to 956)

0.81

375 (-1503 to 2253)

0.70

421 (-1625 to 2466)

0.69

1 Adjusted
2

ref

for age, sex, income, Clavien-Dindo grade, and transplant centre.
Among donors not participating in non-directed or kidney paired donations (n = 757).
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Chapter 6

6

Discussion and Conclusion

The following sections will discuss the findings of this work in the context of the
research questions and hypotheses, draw comparisons to the existing body of evidence,
evaluate the broader societal implications of the results, assess the work’s strengths and
weaknesses, and project the necessary next steps and future directions within the field of
living kidney donor outcomes.

Overview
An overarching goal of this work was to comprehensively characterize the resources and
costs of living kidney donation at a granular level. To our knowledge, our study is the
largest of its kind to prospectively capture the economic outcomes of donors and the first
to evaluate whether some types/groups of donors experience higher costs than others.
Furthermore, our inclusion of kidney paired donors, who face unique donation
circumstances, and a larger sample size, increase the generalizability and accuracy of our
estimates.
Given the consensus within the transplant community and among the general public that
living kidney donors should not be disadvantaged by their gift of life, removing
significant financial hardship is paramount to upholding a just healthcare
system.102,104,178,179 Our finding that donors experience an average total cost of $4790
(median = $2616) throughout the donation process adds to the growing body of evidence
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that living kidney donors experience substantial financial losses due to donation. We
anticipated that our large sample size and a comprehensive micro-costing approach
would offer a more accurate estimate of donor expenses, and more specifically, that our
estimates would exceed those within the existing literature. Our cohort of 912 living
kidney donors incurred an average direct cost of $2110 during donation, higher than
estimates of $1780 (2008 CAD) and $1157 (USD) from previous studies. 1,98 We found
that 18% and 30% of donors experience costs exceeding $8000 and $5000, respectively:
greater than estimates previously reported by Klarenbach et al. (15% of donors with
>$8000 total costs; 2008 CAD) and Rodrigue et al. (20% of donors with >$5000 total
costs; USD).1,98 Beyond this, 13.3% of donors experienced costs in excess of $10,000 and
8.6% of donors incurred costs >25% of their annual household income. Importantly, 28%
of donors incurred total costs exceeding the upper limit of reimbursement offered in
Canada, leaving them with little recourse to shoulder the additional financial burden.
With growing transplant waitlists and stagnating rates of donation, the high costs we
observed demonstrate a need to limit the impact of financial disincentives on living
kidney donation.9
To our knowledge, our study is the first to explore important potential donor subgroup
differences. The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical
Practice Guideline on the Evaluation and Care of Living Kidney Donors highlighted the
need to study approaches to reduce financial disincentives to living donation, “with
particular attention to impact on current disparities in living donor kidney
transplantation”.44 Dew et al. noted gaps in the available evidence regarding the financial
outcomes of donors related to their recipients compared to unrelated donors. 180 Our
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comparisons of costs incurred between donation-type and relationship-type groups
revealed that there are no meaningful differences in the economic outcomes of these
donors. The finding is reassuring given the increasingly critical role kidney paired
donation has assumed in offering life-extending treatment to patients with end-stage
kidney disease. Kidney paired donation has been responsible for over 500 transplants in
Canada since 2009, at a time during which rates of donation have plateaued,
demonstrating the vital role these donors play in meeting the growing demand for
kidneys. The finding that Canadian kidney paired donors do not face higher costs than
other donors is encouraging for the continued success of the program, particularly in the
potential inclusion of directed compatible donor-recipient pairs. 110 Spousal donors are
responsible for about 15% of transplants in Canada, and given the potential additional
financial burden of both the donor and recipient undergoing major surgery, it is
encouraging that this sizeable group of donors does not shoulder significantly greater
indirect and total costs related to loss of income or home productivity, as previously
hypothesized. The findings of our study help contribute to the body of evidence
supporting improved management of the financial consequences of living donation and
the continued growth of kidney paired donation in Canada.
In our secondary analyses, we explored associations between demographic characteristics
and incurred costs, the first time this analysis has been undertaken within a Canadian
group of donors. Our findings that living >100 km from transplant evaluation centre and
being employed are significantly associated with incurred total costs may guide informed
consent practices and prepare donors for the burden of costs they may encounter during
the evaluation and donation process. Rodrigue et al. also found that longer distance to
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transplant program was significantly correlated to financial loss. 98 Our results lend
support to previous work in Australia describing distinct differences between the
financial outcomes of donors living in urban centres as compared to rural donors; the
study’s authors argue that these differences in costs reflect a “rural disadvantage”. 181
Though total costs did not vary across age groups, the drivers of costs differed between
younger and older living kidney donors. Our finding that older donors incurred higher
direct costs possibly reflects additional testing and evaluation in this population due to
comorbidities, and indeed older donors did take more trips to their transplant evaluation
centre and incurred higher travel and accommodation costs. Younger donors, on the other
hand, encountered higher indirect costs than older donors, which reflects differences in
employment and increased number of unpaid days off work and lost wages for younger
donors. Recognizing these important differences in direct and indirect costs incurred by
donors will enable transplant programs to better prepare donor candidates for the
financial losses they may encounter during donation.

Implications
In recent years, the rate of living kidney donation in Canada has plateaued despite an ever
increasing demand.9 In the U.S. these rates have decreased, a finding that has been linked
to recent economic decline, and beyond this, evidence suggests that the disparity in rates
of living donation between low-income and high-income groups has widened over this
same period.116,119 A survey of transplant candidates revealed substantial concern and
reluctance about living kidney donation due to the financial consequences encountered by
donors.182
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A report from Israel demonstrated that the implementation of legislation which reduced
financial disincentives substantially increased the rates of living kidney donation. 183
There is longstanding consensus within the transplant community that donating one’s
kidney should be a financially neutral act.104 A report by Hays et al. offered an
operational definition and a framework for financial neutrality that included medical
costs, travel costs, accommodation costs, and lost wages. 20 The authors further argued
that financial costs affect donor decision making and that achieving financial neutrality
would serve to increase living donation rates.20
A consensus conference on best practices in living kidney donation developed a set of
recommendations on reducing financial barriers to donation. 184 In their report, the authors
argue for a standardized system of reimbursement, legislation that protects employed
donors, development of a financial toolkit , and collection of granular data on costs
incurred by donors.184 Rudow et al. reiterated these practical recommendations by
arguing that cost-effective reimbursement is possible by leveraging the cost savings
associated with living donation.185
Our findings work to advance several of these recommendations, particularly in offering
the granular cost data that allows for the implementation of evidence-based patient
advocacy and education initiatives. This work offers the most comprehensive and
granular understanding of the costs incurred by donors, and the demographic factors
associated with these costs, to date. Our findings support the development of equation
models (to estimate the costs donor candidates may encounter), and a financial toolkit
(which may be used by transplant programs to communicate the financial risks of
donation and refer donors to appropriate resources and services): addressing key evidence
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gaps behind consensus recommendations offered by Tushla et al. in their report.184
Beyond this, understanding and quantifying the economic outcomes of living donation is
paramount to guiding donor informed consent.
Rudow et al. argue that expansions of living kidney donation must be implemented with
knowledge of the risks involved; our finding that kidney paired donors do not face
financial disadvantages compared to other donors ensures that this group of Canadian
donors is protected.185
There is substantial variation in the restrictions and upper limits to reimbursement offered
by provincial programs across Canada. The comprehensive understanding of these costs
by type and magnitude will inform and guide policy governing reimbursement. With 28%
of donors encountering costs in excess of the maximum amount offered by most
programs, it is time to consider a national and comprehensive reimbursement strategy in
Canada.

Strengths
A major strength of this report is the multi-centre prospective cohort study design, with
90% complete follow-up and rigourous statistical methods which accounted for any
missing data (a modern defensible approach to imputation). The statistical analyses were
done with special attention paid the characteristically right-skewed nature of cost data,
and the primary comparisons related to donor relationship type and donation-type were
prespecified to avoid inflating type 1 errors due to multiple testing. Our study captured
the outcomes on 37% of living kidney donors who completed their donation within
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Canada during our recruitment window (from 2009 to 2014). By collecting data for 912
donors across 12 transplant centres coast-to-coast, we circumvent the major criticisms of
previous work for sampling a small, geographically limited, and homogenous group of
donors that is unrepresentative of the larger population. 99
This group of 912 donors represents a sample size over five times larger than the next
leading study in its field, allowing for assessment of important subgroup differences in
financial outcomes. Our sample of donors is the first to include donors participating in
kidney paired donation, a program which began in 2009 in Canada and for which there is
a paucity of outcome data in the literature.
Our pre-specified study protocol and cost-capturing instruments were informed by a pilot
study, allowing for granular, comprehensive, and complete data collection. 1 We achieved
90% follow-up for the 3-month economics assessment, and our group of non-responders
demographically corresponds to non-responders in previous reports: younger, non-white,
un-married, and unemployed.100

Limitations
Some limitations of this work include the generalizability of the findings to other health
care systems, potential underestimation of the true cost borne by donors, incomplete
income data collection, and restricting the scope of cost capturing to living kidney donors
who completed donation.
First, as Canada has a single payer universal health care system, these costs may not
reflect the entire spectrum of costs that may arise in other settings. For example, medical
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costs were not considered during data collection, whereas these costs may be substantial
in non-universal healthcare settings, particularly considering recommendations for longterm monitoring of living kidney donors for adverse outcomes. 186 There is broad
consensus among transplant professionals that living donors should be provided
insurance for long-term follow-up of medical issues related to donation. 186
Second, post-hospital discharge prescription drug coverage varies across provinces; some
donors would qualify for provincial universal outpatient drug coverage. As such, the
reported medication costs may not reflect the true outpatient prescription drug cost.
Beyond this, some donors reported that the transplant centre in which they completed
their evaluation was within a city they reported as an air travel destination. To avoid
unreasonable cost estimates for these patients, we assumed that their ground travel was
local (e.g. hotel to hospital), and assumed no ground travel costs. Lastly, a three month
window for cost collection may not capture expenses incurred by donors encountering
long-term complications necessitating services such as physiotherapy or extended home
care. These assumptions serve to underestimate the true direct costs experienced by these
groups of donors.
Another limitation was the completeness of income data: reporting of income was
optional and data was only available for ~73% of donors, and as such, complete-case
analyses adjusted for income were restricted to this group of donors. We used donor
postal codes and corresponding dissemination areas (by way of the Postal Code
Conversion File provided by Statistics Canada) to obtain donor neighbourhood median
household income and the Canadian Marginalization Index using 2006 census data; we
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performed sensitivity analyses by adding these variables to our model to impute missing
donor household income: our primary results did not change. 187,188
Lastly, cost capturing was restricted to only those living kidney donors who completed
donation. Donor candidates who were evaluated but never donated encounter important
financial consequences during testing and evaluation (e.g. time away from work for
testing).

Future Directions
Living kidney donation is practiced under the tenet that potential risks borne by the donor
are offset by the psychological benefits of altruism.50 With the financial consequences of
donation comprehensively evaluated, there is a pressing need to characterize the potential
impact of costs on the psychosocial and quality of life outcomes of donors to determine if
increased costs undermine this principle. Beyond this, the identification of gaps in
reimbursement in Canada, through comparisons of costs incurred with reimbursement
received, is necessary to appreciate donor net financial loss and the additional cost to the
healthcare system to implement a comprehensive national program. Lastly,
comprehensive and targeted characterization of both modifiable and non-modifiable
drivers of costs incurred by donors would allow transplant programs to mitigate these
financial risks and to better prepare and educate donor candidates they evaluate.
There is considerable debate within the transplant community on the ethics of
incentivizing living kidney donation to increase donation rates. 102,104,178,189 Proponents of
incentives argue that current legislation prohibiting compensation for donation are not
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rooted in evidence and propose that pilot studies are the next critical step to evaluate
potential compensation of donors.178 On the other hand, critics of incentivizing living
donation liken the practice to paying for organs, and instead argue for removal of
disincentives as a priority.104

Conclusion
In this report, we offer compelling evidence that many living kidney donors incur
considerable financial costs while providing the gift of life to patients with end-stage
kidney disease. Each living kidney donation saves the health care system about $250,000
over a five-year period, yet at the same time a substantial number of donors face costs in
excess of reimbursement limits and are left to cope with significant financial loss. There
is a pressing need to remove barriers to donation by leveraging these cost savings to
develop a cost-effective national and comprehensive reimbursement program. Removing
financial disincentives would not only ensure a just and equitable system, but may serve
to increase rates of living donation. The results of this work can be used to guide the
development of policies and programs that safeguard donors from unfair financial risk
and work to meet the growing demand for kidney transplants.

64

References
1.

Klarenbach S, Gill J, Knoll G, et al. Economic Consequences Incurred by Living
Kidney Donors: A Canadian Multi‐Center Prospective Study. American Journal
of Transplantation. 2014;14(4):916-922.

2.

The Kidney Foundation of Canada. Facing the Facts. 2015;
http://www.kidney.ca/file/Facing-the-Facts-2015-infographic-portrait.pdf
Accessed March 10, 2016.

3.

Webster G, Wu J, Williams B, Ivis F, de Sa E, Hall N. Canadian organ
replacement register annual report: treatment of end-stage organ failure in Canada
2003–2012. Ottawa: Canadian Institute for Health Information. 2014.

4.

Moss AH. Improving end-of-life care for dialysis patients. American journal of
kidney diseases. 2005;45(1):209-212.

5.

Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients
on dialysis, patients on dialysis awaiting transplantation, and recipients of a first
cadaveric transplant. New England Journal of Medicine. 1999;341(23):17251730.

6.

Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival
probabilities for dialysis patients vs cadaveric renal transplant recipients. Jama.
1993;270(11):1339-1343.

7.

Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility
of renal transplantation. Kidney international. 1996;50(1):235-242.

8.

Kim SJ, Fenton SS, Kappel J, et al. Organ donation and transplantation in
Canada: insights from the Canadian organ replacement register. Canadian journal
of kidney health and disease. 2014;1(1):1.

9.

Webster G, Wu J, Turner M, Ivis F, de Sa E, Hall N. Canadian organ replacement
register annual report: treatment of end-stage organ failure in Canada 2004–2013.
Ottawa: Canadian Institute for Health Information. 2015.

10.

Axelrod DA, McCullough KP, Brewer ED, Becker BN, Segev DL, Rao PS.
Kidney and pancreas transplantation in the United States, 1999–2008: the
changing face of living donation. American Journal of Transplantation.
2010;10(4p2):987-1002.

11.

Meier-Kriesche H-U, Kaplan B. Waiting time on dialysis as the strongest
modifiable risk factor for renal transplant outcomes: A Paired Donor Kidney
Analysis1. Transplantation. 2002;74(10):1377-1381.

65

12.

Terasaki P, Cecka J, Gjertson D, Takemoto S, Cho Y, Yuge J. Risk rate and longterm kidney transplant survival. Clinical transplants. 1996:443.

13.

Canadian Blood Services. Kidney Paired Donation Program Data Report 20092013. 2015; http://www.organsandtissues.ca/s/wpcontent/uploads/2015/03/Canadian-Blood-Services-KPD-Program-Data-Report2009-2013.pdf. Accessed March 1, 2016.

14.

Jacobs C, Thomas C. Financial considerations in living organ donation. Progress
in Transplantation. 2003;13(2):130-136.

15.

Clarke KS, Klarenbach S, Vlaicu S, Yang RC, Garg AX, Network DNOR. The
direct and indirect economic costs incurred by living kidney donors—a systematic
review. Nephrology Dialysis Transplantation. 2006;21(7):1952-1960.

16.

Getchell LE, McKenzie SQ, Sontrop JM, Hayward JS, McCallum MK, Garg AX.
Increasing the Rate of Living Donor Kidney Transplantation in Ontario: Donorand Recipient-Identified Barriers and Solutions. Canadian journal of kidney
health and disease. 2017;4:2054358117698666.

17.

Hays R, Rodrigue JR, Cohen D, et al. Financial Neutrality for Living Organ
Donors: Reasoning, Rationale, Definitions, and Implementation Strategies.
American Journal of Transplantation. 2016.

18.

Prevalence of Severe Kidney Disease and Use of Dialysis and Transplantation
Across Alberta from 2004 – 2013. Alberta Health Services;2015.

19.

Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with
end-stage renal disease: the impact of dialysis modality and dialysis access.
American Journal of Kidney Diseases. 2002;40(3):611-622.

20.

Hays R, Rodrigue J, Cohen D, et al. Financial neutrality for living organ donors:
reasoning, rationale, definitions, and implementation strategies. American Journal
of Transplantation. 2016;16(7):1973-1981.

21.

Reese PP, Boudville N, Garg AX. Living kidney donation: outcomes, ethics, and
uncertainty. The Lancet. 2015;385(9981):2003-2013.

22.

Sickand M, Cuerden M, Klarenbach S, et al. Reimbursing Live Organ Donors for
Incurred Non‐Medical Expenses: A Global Perspective on Policies and Programs.
American Journal of Transplantation. 2009;9(12):2825-2836.

23.

Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice
guidelines for chronic kidney disease: evaluation, classification, and stratification.
Annals of internal medicine. 2003;139(2):137-147.

66

24.

Obrador GT, Arora P, Kausz AT, Ruthazer R, Pereira BJ, Levey AS. Level of
renal function at the initiation of dialysis in the US end-stage renal disease
population. Kidney international. 1999;56(6):2227-2235.

25.

Stevens PE, Levin A. Evaluation and management of chronic kidney disease:
synopsis of the kidney disease: improving global outcomes 2012 clinical practice
guideline. Annals of internal medicine. 2013;158(11):825-830.

26.

Smith HW. The kidney: structure and function in health and disease. Oxford
University Press, USA; 1951.

27.

Bethesda M. US Renal Data System: USRDS 2003 Annual Data Report: Atlas of
End-Stage Renal Disease in the United States. National Institute of Health,
National Institute of Diabetes and Digestive and Kidney Diseases. 2003.

28.

Wight J, Edwards L, Brazier J, Walters S, Payne J, Brown C. The SF36 as an
outcome measure of services for end stage renal failure. Quality in Health Care.
1998;7(4):209-221.

29.

Merkus MP, Jager KJ, Dekker FW, et al. Quality of life in patients on chronic
dialysis: self-assessment 3 months after the start of treatment. American journal of
kidney diseases. 1997;29(4):584-592.

30.

Lee AJ, Morgan CL, Conway P, Currie CJ. Characterisation and comparison of
health-related quality of life for patients with renal failure. Current medical
research and opinion. 2005;21(11):1777-1783.

31.

Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and
management. American Journal of Kidney Diseases. 2003;42(6):1239-1247.

32.

Manns BJ, Mendelssohn DC, Taub KJ. The economics of end-stage renal disease
care in Canada: incentives and impact on delivery of care. International journal of
health care finance and economics. 2007;7(2-3):149-169.

33.

Klarenbach SW, Tonelli M, Chui B, Manns BJ. Economic evaluation of dialysis
therapies. Nature Reviews Nephrology. 2014;10(11):644-652.

34.

Zelmer J. The economic burden of end-stage renal disease in Canada. Kidney
international. 2007;72(9):1122-1129.

35.

Devins GM, Binik YM, Hutchinson TA, Hollomby DJ, Barré PE, Guttmann RD.
The emotional impact of end-stage renal disease: Importance of patients'
perceptions of intrusiveness and control. The International Journal of Psychiatry
in Medicine. 1984;13(4):327-343.

36.

Belasco AG, Sesso R. Burden and quality of life of caregivers for hemodialysis
patients. American journal of kidney diseases. 2002;39(4):805-812.

67

37.

Daugirdas JT, Blake PG, Ing TS. Handbook of dialysis. Lippincott Williams &
Wilkins; 2012.

38.

Klarenbach S, Tonelli M, Pauly R, et al. Economic evaluation of frequent home
nocturnal hemodialysis based on a randomized controlled trial. Journal of the
American Society of Nephrology. 2014;25(3):587-594.

39.

Lukowsky LR, Mehrotra R, Kheifets L, Arah OA, Nissenson AR, Kalantar-Zadeh
K. Comparing mortality of peritoneal and hemodialysis patients in the first 2
years of dialysis therapy: a marginal structural model analysis. Clinical Journal of
the American Society of Nephrology. 2013;8(4):619-628.

40.

Weinhandl ED, Foley RN, Gilbertson DT, Arneson TJ, Snyder JJ, Collins AJ.
Propensity-matched mortality comparison of incident hemodialysis and peritoneal
dialysis patients. Journal of the American Society of Nephrology. 2010;21(3):499506.

41.

Schaubel DE, Morrison HI, Fenton S. Comparing mortality rates on CAPD/CCPD
and hemodialysis. The Canadian experience: fact or fiction? Peritoneal dialysis
international. 1998;18(5):478-484.

42.

Knoll GA, Tinckam KJ. Organ Donation and Transplantation: The View From
Canada. Transplantation. 2015;99(11):2231-2233.

43.

Merrill JP, Murray JE, Harrison JH, Guild WR. Successful homotransplantation
of the human kidney between identical twins. Journal of the American Medical
Association. 1956;160(4):277-282.

44.

Lentine KL, Kasiske BL, Levey AS, et al. KDIGO Clinical Practice Guideline on
the Evaluation and Care of Living Kidney Donors. Transplantation. 2017;101(8S
Suppl 1):S1-s109.

45.

Barnieh L, Manns B, Klarenbach S, McLaughlin K, Yilmaz S, Hemmelgarn B. A
description of the costs of living and standard criteria deceased donor kidney
transplantation. American Journal of Transplantation. 2011;11(3):478-488.

46.

Gentry SE, Montgomery RA, Segev DL. Kidney paired donation: fundamentals,
limitations, and expansions. American Journal of Kidney Diseases.
2011;57(1):144-151.

47.

Cole EH, Nickerson P, Campbell P, et al. The Canadian kidney paired donation
program: a national program to increase living donor transplantation.
Transplantation. 2015;99(5):985-990.

48.

Klarenbach S, Garg AX, Vlaicu S. Living organ donors face financial barriers: A
national reimbursement policy is needed. Canadian Medical Association Journal.
2006;174(6):797-798.

68

49.

Fortin M-C, Williams-Jones B. Who should travel in kidney exchange programs:
the donor, or the organ? Open Medicine. 2011;5(1):e23.

50.

Clemens K, Thiessen‐Philbrook H, Parikh C, et al. Psychosocial health of living
kidney donors: a systematic review. American Journal of Transplantation.
2006;6(12):2965-2977.

51.

Segev DL, Muzaale AD, Caffo BS, et al. Perioperative mortality and long-term
survival following live kidney donation. Jama. 2010;303(10):959-966.

52.

Mjøen G, Øyen O, Holdaas H, Midtvedt K, Line P-D. Morbidity and mortality in
1022 consecutive living donor nephrectomies: benefits of a living donor registry.
Transplantation. 2009;88(11):1273-1279.

53.

Okamoto M, Akioka K, Nobori S, et al. Short-and long-term donor outcomes after
kidney donation: analysis of 601 cases over a 35-year period at Japanese single
center. Transplantation. 2009;87(3):419-423.

54.

Garg A, Muirhead N, Knoll G, et al. Proteinuria and reduced kidney function in
living kidney donors: a systematic review, meta-analysis, and meta-regression.
Kidney international. 2006;70(10):1801-1810.

55.

Srinivas TR, Poggio ED. Do living kidney donors have CKD? Advances in
chronic kidney disease. 2012;19(4):229-236.

56.

Matas AJ, Ibrahim HN. The unjustified classification of kidney donors as patients
with CKD: critique and recommendations. Clinical Journal of the American
Society of Nephrology. 2013;8(8):1406-1413.

57.

Consortium CKDP. Association of estimated glomerular filtration rate and
albuminuria with all-cause and cardiovascular mortality in general population
cohorts: a collaborative meta-analysis. The Lancet. 2010;375(9731):2073-2081.

58.

Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation.
New England Journal of Medicine. 2009;360(5):459-469.

59.

Cherikh W, Young C, Kramer B, Taranto S, Randall H, Fan PY. Ethnic and
Gender Related Differences in the Risk of End‐Stage Renal Disease After Living
Kidney Donation. American Journal of Transplantation. 2011;11(8):1650-1655.

60.

Fehrman-Ekholm I, Dunér F, Brink B, Tydén G, Elinder C-G. No Evidence of
Accelerated Loss of Kidney Function in Living Kidney Donors: Results From A
Cross-Sectional Follow-Up1. Transplantation. 2001;72(3):444-449.

61.

Muzaale AD, Massie AB, Wang M-C, et al. Risk of end-stage renal disease
following live kidney donation. Jama. 2014;311(6):579-586.

69

62.

Mjøen G, Hallan S, Hartmann A, et al. Long-term risks for kidney donors. Kidney
international. 2014;86(1):162-167.

63.

Reese P, Bloom R, Feldman H, et al. Mortality and cardiovascular disease among
older live kidney donors. American Journal of Transplantation. 2014;14(8):18531861.

64.

Garg AX, Meirambayeva A, Huang A, et al. Cardiovascular disease in kidney
donors: matched cohort study. Bmj. 2012;344:e1203.

65.

Garg AX, Nevis IF, McArthur E, et al. Gestational hypertension and preeclampsia
in living kidney donors. New England Journal of Medicine. 2015;372(2):124-133.

66.

Thomas S, Lam N, Welk B, et al. Risk of kidney stones with surgical intervention
in living kidney donors. American Journal of Transplantation. 2013;13(11):29352944.

67.

Garg AX, Pouget J, Young A, et al. Fracture risk in living kidney donors: a
matched cohort study. American Journal of Kidney Diseases. 2012;59(6):770776.

68.

Thomas SM, Lam NN, Huang A, et al. Risk of serious gastrointestinal bleeding in
living kidney donors. Clinical transplantation. 2014;28(5):530-539.

69.

Tong A, Chapman JR, Wong G, de Bruijn J, Craig JC. Screening and follow-up
of living kidney donors: a systematic review of clinical practice guidelines.
Transplantation. 2011;92(9):962-972.

70.

Parekh AM, Gordon EJ, Garg AX, Waterman AD, Kulkarni S, Parikh CR. Living
kidney donor informed consent practices vary between US and non-US centers.
Nephrology Dialysis Transplantation. 2008;23(10):3316-3324.

71.

Prandini R, Bonomini V, Vangelista A, et al. Living donors in renal
transplantation: a long-term study. Paper presented at: Transplantation
proceedings1987.

72.

Schover LR, Streem SB, Boparai N, Duriak K, Novick AC. The psychosocial
impact of donating a kidney: long-term followup from a urology based center.
The Journal of urology. 1997;157(5):1596-1601.

73.

Johnson EM, Anderson JK, Jacobs C, et al. LONG-TERM FOLLOW-UP OF
LIVING KIDNEY DONORS: QUALITY OF LIFE AFTER DONATION1.
Transplantation. 1999;67(5):717-721.

74.

Fisher PA, Kropp DJ, Fleming EA. Impact on living kidney donors: Quality of
life, self-image and family dynamics. Nephrology Nursing Journal.
2005;32(5):489.

70

75.

Minz M, Udgiri N, Sharma A, et al. Prospective psychosocial evaluation of
related kidney donors: Indian perspective. Paper presented at: Transplantation
proceedings2005.

76.

Tanriverdi N, Özçürümez G, Colak T, et al. Quality of life and mood in renal
transplantation recipients, donors, and controls: preliminary report. Paper
presented at: Transplantation proceedings2004.

77.

Duque JLF, Loughlin KR, Kumar S. Morbidity of flank incision for renal donors.
Urology. 1999;54(5):796-801.

78.

Corley MC, Elswick R, Sargeant CC, Scott S, Welch JL. Attitude, self-image, and
quality of life of living kidney donors/Commentary and response. Nephrology
Nursing Journal. 2000;27(1):43.

79.

Clemens K, Boudville N, Dew M, et al. The Long‐Term Quality of Life of Living
Kidney Donors: A Multicenter Cohort Study. American Journal of
Transplantation. 2011;11(3):463-469.

80.

Timmerman L, Laging M, Westerhof G, et al. Mental health among living kidney
donors: a prospective comparison with matched controls from the general
population. American journal of transplantation. 2015;15(2):508-517.

81.

Jacobs CL, Gross CR, Messersmith EE, et al. Emotional and financial experiences
of kidney donors over the past 50 Years: The RELIVE study. Clinical Journal of
the American Society of Nephrology. 2015:CJN. 07120714.

82.

Waterman AD, Covelli T, Caisley L, et al. Potential living kidney donors' health
education use and comfort with donation. Progress in Transplantation.
2004;14(3):233-240.

83.

Hiller J, Sroka M, Weber R, Morrison AS, Ratner LE. Identifying donor concerns
to increase live organ donation. Progress in Transplantation. 1998;8(1):51-54.

84.

Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods
for the economic evaluation of health care programmes. Oxford university press;
2015.

85.

Smith MD, Kappell DF, Province MA, et al. Living-related kidney donors: a
multicenter study of donor education, socioeconomic adjustment, and
rehabilitation. American Journal of Kidney Diseases. 1986;8(4):223-233.

86.

Wolters H, Heidenreich S, Senninger N. Living donor kidney transplantation:
chance for the recipient—financial risk for the donor? Paper presented at:
Transplantation proceedings2003.

71

87.

Lyons K, Shallcross J, Bakran A. Eight years experience of reimbursement costs
associated with an active living kidney donor programme. Transplantation.
2004;78(2):2-3.

88.

Zuidema W, Tronchet N, Luchtenburg A, de Klerk M, IJzermans J, Weimar W.
Nonresident living kidney donors. Paper presented at: Transplantation
proceedings2005.

89.

Giessing M, Reuter S, Schönberger B, et al. Quality of life of living kidney
donors in Germany: a survey with the Validated Short Form-36 and Giessen
Subjective Complaints List-24 questionnaires. Transplantation. 2004;78(6):864872.

90.

Liounis B, Roy LP, Thompson JF, May J, Sheil A. The living, related kidney
donor: a follow-up study. The Medical Journal of Australia. 1988;148(9):436437,440-434.

91.

Stothers L, Gourlay WA, Liu L. Attitudes and predictive factors for live kidney
donation: a comparison of live kidney donors versus nondonors. Kidney
international. 2005;67(3):1105-1111.

92.

Isotani S, Fujisawa M, Ichikawa Y, et al. Quality of life of living kidney donors:
the short-form 36-item health questionnaire survey. Urology. 2002;60(4):588-592.

93.

Westlie L, Leivestad T, Holdaas H, Lien B, Meyer K, Fauchald P. Report from
the Norwegian national hospitals living donor registry: One-year data, January 1,
2002. Paper presented at: Transplantation proceedings2003.

94.

Cabrer C, Oppenhaimer F, Manyalich M, et al. The living kidney donation
process: the donor perspective. Paper presented at: Transplantation
proceedings2003.

95.

Vlaovic PD, Devins G, Abbey S, Wright E, Robinette M. Psychosocial impact of
renal donation. The Canadian journal of urology. 1999;6(5):859-864.

96.

McCune TR, Armata T, Mendez‐Picon G, et al. The Living Organ Donor
Network: a model registry for living kidney donors. Clinical transplantation.
2004;18(s12):33-38.

97.

Rodrigue J, Schold J, Morrissey P, et al. Predonation direct and indirect costs
incurred by adults who donated a kidney: findings from the KDOC study.
American Journal of Transplantation. 2015;15(9):2387-2393.

98.

Rodrigue J, Schold J, Morrissey P, et al. Direct and indirect costs following living
kidney donation: Findings from the KDOC study. American Journal of
Transplantation. 2016.

72

99.

Formica R, Newell K. What Is the Price of Altruism? American Journal of
Transplantation. 2016.

100.

Wiseman J, Jacobs C, Larson D, et al. Financial Burden Borne by Laparoscopic
Living Kidney Donors. Transplantation. 2016.

101.

Boulware L, Troll M, Wang N, Powe N. Public attitudes toward incentives for
organ donation: a national study of different racial/ethnic and income groups.
American Journal of Transplantation. 2006;6(11):2774-2785.

102.

Tong A, Chapman JR, Wong G, Craig JC. Perspectives of transplant physicians
and surgeons on reimbursement, compensation, and incentives for living kidney
donors. American Journal of Kidney Diseases. 2014;64(4):622-632.

103.

Vlaicu S, Klarenbach S, Yang RC, Dempster T, Garg AX. Current Canadian
initiatives to reimburse live organ donors for their non-medical expenses.
Canadian Journal of Public Health/Revue Canadienne de Sante'e Publique.
2007:481-483.

104.

Delmonico F, Martin D, Domínguez‐Gil B, et al. Living and deceased organ
donation should be financially neutral acts. American Journal of Transplantation.
2015;15(5):1187-1191.

105.

LaPointe Rudow D, Hays R, Baliga P, et al. Consensus conference on best
practices in live kidney donation: recommendations to optimize education, access,
and care. American Journal of Transplantation. 2015;15(4):914-922.

106.

American Medical Association. Opinion 2.15 - Transplantation of Organs from
Living Donors. 2011; http://www.ama-assn.org/ama/pub/physicianresources/medical-ethics/code-medical-ethics/opinion215.page? . Accessed
March 10, 2016.

107.

Caulfield T, Nelson E, Goldfeldt B, Klarenbach S. Incentives and organ donation:
what’s (really) legal in Canada? Canadian journal of kidney health and disease.
2014;1(1):1.

108.

Province of Alberta. Human Tissue and Organ Donation Act. Chapter H-14.5.
Section 3(2). Statutes of Alberta; 2006.

109.

Allen MB, Reese PP. Financial incentives for living kidney donation: ethics and
evidence. Clinical Journal of the American Society of Nephrology.
2013;8(12):2031-2033.

110.

Hendren E, Gill J, Landsberg D, Dong J, Rose C, Gill JS. Willingness of Directed
Living Donors and Their Recipients to Participate in Kidney Paired Donation
Programs. Transplantation. 2015;99(9):1894-1899.

73

111.

Barnieh L, Gill JS, Klarenbach S, Manns BJ. The cost-effectiveness of using
payment to increase living donor kidneys for transplantation. Clinical Journal of
the American Society of Nephrology. 2013:CJN. 03350313.

112.

Gill JS, Klarenbach S, Barnieh L, et al. Financial incentives to increase Canadian
organ donation: quick fix or fallacy? American Journal of Kidney Diseases.
2014;63(1):133-140.

113.

Martin DE, White SL. Financial Incentives for Living Kidney Donors: Are They
Necessary? American Journal of Kidney Diseases. 2015;66(3):389-395.

114.

Gerard MYL. REMOVING FINANCIAL BARRIERS TO LIVING ORGAN
DONATION: BRITISH COLUMBIA PILOTS EXPENSE REIMBURSEMENT:
901. Transplantation. 2008;86(2S):314.

115.

Knotts R, Finn WF, Armstrong T. Psychosocial factors impacting patients,
donors, and nondonors involved in renal transplant evaluation. Perspect.
1996;15:11-23.

116.

Gill J, Gill J, Barnieh L, et al. Income of living kidney donors and the income
difference between living kidney donors and their recipients in the United States.
American Journal of Transplantation. 2012;12(11):3111-3118.

117.

Thiessen C, Jaji Z, Joyce M, et al. Opting out: a single-centre pilot study assessing
the reasons for and the psychosocial impact of withdrawing from living kidney
donor evaluation. Journal of Medical Ethics. 2017:medethics-2016-103512.

118.

Rodrigue JR, Schold JD, Mandelbrot DA, Taber DJ, Phan V, Baliga PK. Concern
for lost income following donation deters some patients from talking to potential
living donors. Progress in Transplantation. 2016;26(4):292-298.

119.

Rodrigue JR, Schold JD, Mandelbrot DA. The decline in living kidney donation
in the United States: random variation or cause for concern? Transplantation.
2013;96(9).

120.

Gill J, Dong J, Gill J. Population income and longitudinal trends in living kidney
donation in the United States. Journal of the American Society of Nephrology.
2015;26(1):201-207.

121.

Guyatt GH, Sackett DL, Sinclair JC, et al. Users' guides to the medical literature:
IX. A method for grading health care recommendations. Jama.
1995;274(22):1800-1804.

122.

Kristman V, Manno M, Côté P. Loss to follow-up in cohort studies: how much is
too much? European journal of epidemiology. 2004;19(8):751-760.

123.

Aitken L, Gallagher R, Madronio C. Principles of recruitment and retention in
clinical trials. International journal of nursing practice. 2003;9(6):338-346.

74

124.

Robinson KA, Dennison CR, Wayman DM, Pronovost PJ, Needham DM.
Systematic review identifies number of strategies important for retaining study
participants. Journal of clinical epidemiology. 2007;60(8):757. e751-757. e719.

125.

Mapstone J, Elbourne D, Roberts IG. Strategies to improve recruitment to
research studies. The Cochrane Library. 2007.

126.

Evans C, Crawford B. Patient self-reports in pharmacoeconomic studies.
Pharmacoeconomics. 1999;15(3):241-256.

127.

Revicki DA, Irwin D, Reblando J, Simon GE. The accuracy of self-reported
disability days. Medical care. 1994;32(4):401-404.

128.

Gold M, Siegel J, Russel L, Weinstein M. Cost-effectiveness in Health and
Medicine. New York: Oxford University Press; 1996.

129.

Statistics Canada. Meal and vehicle rates used to calculate travel expenses for
2016 and previous years. 2017; http://www.cra-arc.gc.ca/travelcosts/. Accessed
June 27, 2017.

130.

Statistics Canada. Labour force survey estimates (LFS), wages of employees by
job permanence, union coverage, sex and age group

annual (current dollars). 2017;
http://www5.statcan.gc.ca/cansim/a26?lang=eng&id=2820074#F7. Accessed July
27, 2016.
131.

Krol M, Brouwer W. How to estimate productivity costs in economic evaluations.
Pharmacoeconomics. 2014;32(4):335-344.

132.

Statistics Canada. Average hourly earnings (including overtime) for employees
paid by the hour, by province and territory. 2017; http://www.statcan.gc.ca/tablestableaux/sum-som/l01/cst01/labr80-eng.htm. Accessed June 27, 2017.

133.

Statistics Canada. Consumer Price Index, historical summary (1996 to 2016).
2017; http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/econ46aeng.htm. Accessed June 27, 2017.

134.

Little RJ, Rubin DB. Statistical analysis with missing data. John Wiley & Sons;
2014.

135.

Rubin DB. Inference and missing data. Biometrika. 1976;63(3):581-592.

136.

Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied methods of
cost-effectiveness analysis in healthcare. Vol 3: OUP Oxford; 2010.

75

137.

Burton A, Billingham LJ, Bryan S. Cost-effectiveness in clinical trials: using
multiple imputation to deal with incomplete cost data. Clinical Trials.
2007;4(2):154-161.

138.

Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in
cost-effectiveness analysis conducted within randomised controlled trials.
PharmacoEconomics. 2014;32(12):1157-1170.

139.

Stata 14 Multiple Imputation Reference Manual [computer program]. College
Station, TX: StataCorp LP; 2015.

140.

Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained
equations: what is it and how does it work? International journal of methods in
psychiatric research. 2011;20(1):40-49.

141.

Mistler SA, Enders CK. A Comparison of Joint Model and Fully Conditional
Specification Imputation for Multilevel Missing Data. Journal of Educational and
Behavioral Statistics. 2016:1076998617690869.

142.

White IR, Royston P, Wood AM. Multiple imputation using chained equations:
issues and guidance for practice. Statistics in medicine. 2011;30(4):377-399.

143.

Stata Statistical Software: Release 14 [computer program]. College Station, TX:
StataCorp LP; 2015.

144.

Little RJ. Missing-data adjustments in large surveys. Journal of Business &
Economic Statistics. 1988;6(3):287-296.

145.

Morris TP, White IR, Royston P. Tuning multiple imputation by predictive mean
matching and local residual draws. BMC medical research methodology.
2014;14(1):1.

146.

Vroomen JM, Eekhout I, Dijkgraaf MG, et al. Multiple imputation strategies for
zero-inflated cost data in economic evaluations: which method works best? The
European Journal of Health Economics. 2015:1-12.

147.

Rubin DB. Multiple imputation for nonresponse in surveys. Vol 81: John Wiley &
Sons; 2004.

148.

Duan N. Smearing estimate: a nonparametric retransformation method. Journal of
the American Statistical Association. 1983;78(383):605-610.

149.

Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical
trials. OUP Oxford; 2014.

150.

Ramsey S, Willke R, Briggs A, et al. Best practices for economic analysis
alongside clinical trials: an ISPOR RCT-CEA Task Force report. 2004.

76

151.

Thompson SG, Barber JA. How should cost data in pragmatic randomised trials
be analysed? Bmj. 2000;320(7243):1197-1200.

152.

Doshi JA, Glick HA, Polsky D. Analyses of cost data in economic evaluations
conducted alongside randomized controlled trials. Value in Health.
2006;9(5):334-340.

153.

Wilcoxon F. Individual comparisons by ranking methods. Biometrics bulletin.
1945;1(6):80-83.

154.

Barber JA, Thompson SG. Analysis of cost data in randomized trials: an
application of the non‐parametric bootstrap. Statistics in medicine.
2000;19(23):3219-3236.

155.

Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence
intervals, and other measures of statistical accuracy. Statistical science. 1986:5475.

156.

Efron BT. RJ (1993). An introduction to the bootstrap. Monograps on Statistics
and Applied Probability. 1993;57.

157.

Briggs AH, Wonderling DE, Mooney CZ. Pulling cost‐effectiveness analysis up
by its bootstraps: A non‐parametric approach to confidence interval estimation.
Health economics. 1997;6(4):327-340.

158.

Efron B. Better bootstrap confidence intervals. Journal of the American statistical
Association. 1987;82(397):171-185.

159.

Cuzick J. A wilcoxon‐type test for trend. Statistics in medicine. 1985;4(4):543547.

160.

Jones AM, Rice N, d'Uva TB, Balia S. Applied health economics. Routledge;
2013.

161.

Doshi J, Glick H. Evaluating Patient Level Costs. 2009.

162.

Pregibon D. Goodness of link tests for generalized linear models. Applied
statistics. 1980:15-14.

163.

Hosmer Jr DW, Lemeshow S, Sturdivant RX. Applied logistic regression. Vol
398: John Wiley & Sons; 2013.

164.

Manning WG, Mullahy J. Estimating log models: to transform or not to
transform? Journal of health economics. 2001;20(4):461-494.

165.

McCullagh P, Nelder JA. Generalized linear models. Vol 37: CRC press; 1989.

77

166.

Ender P. collin”: Stata command to compute collinearity diagnostics. UCLA:
Academic Technology Services, Statistical Consulting Group Accessed. 2010;4.

167.

Williams R. Using the margins command to estimate and interpret adjusted
predictions and marginal effects. Stata Journal. 2012;12(2):308.

168.

Owens G. Gender differences in health care expenditures, resource utilization,
and quality of care. Journal of Managed Care Pharmacy. 2008;14(3):2-6.

169.

Alemayehu B, Warner KE. The lifetime distribution of health care costs. Health
services research. 2004;39(3):627-642.

170.

Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their
predictors in patients with rheumatoid arthritis. Arthritis & Rheumatism.
2003;48(10):2750-2762.

171.

Gabriel SE, Tosteson AN, Leibson CL, et al. Direct medical costs attributable to
osteoporotic fractures. Osteoporosis International. 2002;13(4):323-330.

172.

Krell RW, Girotti ME, Dimick JB. Extended length of stay after surgery:
complications, inefficient practice, or sick patients? JAMA surgery.
2014;149(8):815-820.

173.

Lawson EH, Hall BL, Louie R, et al. Association between occurrence of a
postoperative complication and readmission: implications for quality
improvement and cost savings. Annals of surgery. 2013;258(1):10-18.

174.

Dimick JB, Chen SL, Taheri PA, Henderson WG, Khuri SF, Campbell DA.
Hospital costs associated with surgical complications: a report from the privatesector National Surgical Quality Improvement Program. Journal of the American
College of Surgeons. 2004;199(4):531-537.

175.

Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a
new proposal with evaluation in a cohort of 6336 patients and results of a survey.
Annals of surgery. 2004;240(2):205-213.

176.

Sanmartin C, Hennessy D, Lu Y, Law MR. Trends in out-of-pocket health care
expenditures in Canada, by household income, 1997 to 2009. Health reports.
2014;25(4):13.

177.

Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) statement: guidelines for
reporting observational studies. Preventive medicine. 2007;45(4):247-251.

178.

Peters TG, Fisher JS, Gish RG, Howard RJ. Views of US voters on compensating
living kidney donors. JAMA surgery. 2016;151(8):710-716.

78

179.

Barnieh L, Klarenbach S, Gill JS, Caulfield T, Manns B. Attitudes toward
strategies to increase organ donation: views of the general public and health
professionals. Clinical Journal of the American Society of Nephrology.
2012;7(12):1956-1963.

180.

Dew MA, Myaskovsky L, Steel JL, DiMartini AF. Managing the psychosocial
and financial consequences of living donation. Current transplantation reports.
2014;1(1):24-34.

181.

McGrath P, Holewa H. It’sa regional thing’: financial impact of renal
transplantation on live donors. Rural and remote health. 2012;12(2144).

182.

Rodrigue JR, Cornell DL, Kaplan B, Howard RJ. Patients' willingness to talk to
others about living kidney donation. Progress in Transplantation. 2008;18(1):2531.

183.

Lavee J, Ashkenazi T, Stoler A, Cohen J, Beyar R. Preliminary marked increase
in the national organ donation rate in Israel following implementation of a new
organ transplantation law. American Journal of Transplantation. 2013;13(3):780785.

184.

Tushla L, Rudow DL, Milton J, Rodrigue JR, Schold JD, Hays R. Living-donor
kidney transplantation: reducing financial barriers to live kidney donation—
recommendations from a consensus conference. Clinical Journal of the American
Society of Nephrology. 2015;10(9):1696-1702.

185.

Rudow DL, Cohen D. Practical Approaches to Mitigating Economic Barriers to
Living Kidney Donation for Patients and Programs. Current Transplantation
Reports. 2017;4(1):24-31.

186.

Dew A, Garvey C, Gaston R, et al. Living kidney donor follow-up: state-of-theart and future directions, conference summary and recommendations. American
Journal of Transplantation. 2011;11:2561-2568.

187.

Statistics Canada. Postal CodeOM Conversion File Plus (PCCF). Ottawa, Canada:
Minister of Industry;. 2013, Catalogue no. 92-154-X.

188.

Matheson FI, Dunn JR, Smith KL, Moineddin R, Glazier RH. Development of the
Canadian Marginalization Index: a new tool for the study of inequality. Canadian
Journal of Public Health/Revue Canadienne de Sante'e Publique. 2012:S12-S16.

189.

Matas AJ. The Rationale for Incentives for Living Donors: An International
Perspective? Current Transplantation Reports. 2015;2(1):44-51.

79

Appendices
Appendix A: LKD Study protocol approval by The University of Western
Ontario Research Ethics Board for Health Sciences Research Involving
Human Subjects
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Appendix B: The twelve major transplant centres across Canada participating in
the Living Kidney Donor Study

Table 11. The major transplant centres participating in the LKD Study and their donor
recruitment numbers.
Study
Centre ID

Donors
Recruited

Kidney Transplant Centre

City

001

London Health Sciences Centre

London, ON

77

002

St. Paul’s Hospital

Vancouver, BC

180

003

The Ottawa Hospital

Ottawa, ON

91

005

Queen Elizabeth II Hospital

Halifax, NS

27

006

St. Michael's Hospital

Toronto, ON

74

007

St. Joseph's Hospital

Hamilton, ON

27

008

Health Sciences Centre

Winnipeg, MB

37

009

University of Alberta

Edmonton, AB

90

017

Toronto General Hospital

Toronto, ON

111

018

Foothills Medical Centre

Calgary, AB

45

019

Vancouver General Hospital

Vancouver, BC

94

020

Montreal General Hospital

Montreal, QC

46
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Appendix C: LKD Study retention flowchart and worksheets for missing
and late 3 month assessments.
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Appendix D: Economic case report forms for 3-month and one-year
assessments
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Appendix E: Costing rates used in the valuation of resources
Table 12. 2016 kilometric travel rates for provinces and territories
Province

Kilometric Rate
(2016 CAD/km)

Newfoundland

0.530

Prince Edward Island

0.475

Nova Scotia

0.485

New Brunswick

0.485

Quebec

0.495

Ontario

0.540

Manitoba

0.470

Saskatchewan

0.455

Alberta

0.435

British Columbia

0.475

Yukon

0.590

Northwest Territories

0.580

Nunavut

0.575

From: http://www.cra-arc.gc.ca/travelcosts/
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Table 13. Individual and average hotel rates with applicable taxes (2016 CAD). a

Surgery
Hospital

Foothills
Medical Centre

City

Calgary, AB

Hôpital
Maisonneuve-

Montreal, QC

Rosemont

Health
Sciences
Centre

Hôtel-Dieu de
Québec

University
Hospital

Montreal
General
Hospital

Winnipeg, MB

Quebec City, QC

London, ON

Montreal, QC

Hotels

Hotel Cost
(CAD/night)

Hotel Alma

91.84

Ramada Limited
Calgary Northwest

104.16

Best Western Village
Park Inn

132.16

Le Chablis

118.48

Hotel University
Montreal

140.99

Days Inn Montreal
East

119.66

Canad Inns Destination
Centre – Health
Sciences Centre

140.42

Econo Lodge

89.68

Hotel Royal Plaza

88.50

Fairmont Le Château
Frontenac

199.42

Hôtel de VieuxQuébec

158.12

Hotel Champlain
Vieux-Quebec

88.5

Guest House on the
Mount

66.67

The Windermere
Manor

158.20

Ivey Spencer
Leadership Centre

122.04

Chateau Versailles
Hotel Montreal

143.35

Le Méridien Versailles

176.53

Le Saint-Malo Hotel

79.38

Average
Hotel Cost
(CAD/night)

109.39

126.37

106.20

148.68

115.64

133.09
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Hôpital Notre
Dame

The Ottawa
Hospital

Montreal, QC

Ottawa, ON

QEII Health
Sciences

Halifax, NS

Centre

Royal Victoria
Hospital

St. Joseph’s
Healthcare
Hamilton

St. Michael's
Hospital

St. Paul's
Hospital

Montreal, QC

Hamilton, ON

Toronto, ON

Vancouver, BC

Hotel Dorion

73.45

Hotel Chateau de
L’Argoat

136.25

Kutuma Hotel &
Suites

150.46

Best Western PLUS
Ottawa City Centre

151.96

Travelodge Ottawa
West

120.64

Richmond Plaza Motel

91.64

Atlantica Hotel Halifax

153.27

Courtyard Halifax
Downtown

209.43

The Lord Nelson Hotel
& Suites

162.63

Le Chabrol

112.55

La Tour Belvedere

99.52

Residence Inn
Montreal Westmount

164.68

Homewood Suites by
Hilton

170.63

Staybridge Suites
Hamilton – Downtown

159.33

Sheraton Hamilton
Hotel

145.77

Bond Place Hotel

117.16

Chelsea Hotel

183.28

The Grand Hotel &
Suites

215.76

Ramada Vancouver
Downtown

103.24

Wedgewood Hotel &
Spa Vancouver

184.44

The Fairmont Hotel
Vancouver

161.24

120.05

121.41

175.11

125.58

158.58

172.07

149.64
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Toronto
General
Hospital

University of
Alberta
Hospital

Vancouver
General
Hospital

St. Paul’s
Hospital
a

Toronto, ON

Edmonton, AB

Vancouver. BC

Saskatoon, SK

Discussion of prices in section 4.2.4.3.

DoubleTree by Hilton
Hotel Toronto
Downtown

222.71

Chelsea Hotel

183.28

BeSixFifty Hotel

212.28

Campus Tower Suite
Hotel

220.64

Varscona Hotel on
Whyte

184.80

Mettera Hotel on
Whyte

217.28

Holiday Inn
Vancouver – Centre
(Broadway)

160.08

Granville Island Hotel

287.68

Executive Hotel
Vintage Park
Vancouver

117.16

Super 8 Saskatoon

123.20

Holiday Inn Saskatoon

152.32

Hilton Garden Inn

206.08

206.09

207.57

188.31

160.53
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Table 14. Applicable taxes on accommodations in each province.
Province/City

Applicable Taxes and Fees

Alberta

= 12% (5% GST + 4% levy + 3% DMF)

British Columbia

= 16% (5% GST + 8% PST (for accommodation) + 3% DMF)

Manitoba

= 18% (5% GST + 8% PST + 5% DMF)

Nova Scotia

= 17% (15% HST + 2% DMF)

Saskatchewan

= 12% (5% GST + 5% PST + 2% DMF)

Ontario
Toronto

16% (13% HST + 3% DMF)

Ottawa

16% (13% HST + 3% DMF)

Hamilton

13% (13% HST)

London

13% (13% HST)

Quebec
Montreal

= 18.475% (5% GST + 9.975 PST + 3.5% DMF)

Quebec City

= 17.975% (5% GST + 9.975 PST + 3% DMF)

GST = federal goods and services tax, PST = provincial sales tax, HST = harmonized sales tax, DMF =
tourism levies or destination marketing fees
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Table 15. Average age-, sex-, and province-specific wage rates (2016 CAD).
Province1

Sex

Males
Newfoundland and
Labrador
Females

Males
Prince Edward Island
Females

Males
Nova Scotia
Females

Males
New Brunswick
Females

Males
Quebec
Females

Age group

Average wage rate
(2016 CAD)

15 to 24 years

14.95

25 to 54 years

28.95

55 years and over

26.44

15 to 24 years

14.08

25 to 54 years

24.02

55 years and over

20.44

15 to 24 years

13.47

25 to 54 years

23.29

55 years and over

22.59

15 to 24 years

12.92

25 to 54 years

22.63

55 years and over

21.32

15 to 24 years

13.86

25 to 54 years

25.53

55 years and over

25.40

15 to 24 years

13.72

25 to 54 years

23.53

55 years and over

22.62

15 to 24 years

13.50

25 to 54 years

24.58

55 years and over

23.46

15 to 24 years

13.27

25 to 54 years

22.88

55 years and over

19.99

15 to 24 years

14.95

25 to 54 years

27.72

55 years and over

26.49

15 to 24 years

13.89

25 to 54 years

24.97

55 years and over

22.18
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Males
Ontario
Females

Males
Manitoba
Females

Males
Saskatchewan
Females

Males
Alberta
Females

Males
British Columbia
Females

15 to 24 years

14.78

25 to 54 years

30.28

55 years and over

30.29

15 to 24 years

13.91

25 to 54 years

26.37

55 years and over

26.00

15 to 24 years

14.94

25 to 54 years

26.44

55 years and over

26.91

15 to 24 years

14.15

25 to 54 years

23.86

55 years and over

24.84

15 to 24 years

17.61

25 to 54 years

30.91

55 years and over

31.85

15 to 24 years

15.76

25 to 54 years

26.40

55 years and over

26.34

15 to 24 years

18.08

25 to 54 years

35.14

55 years and over

34.93

15 to 24 years

16.32

25 to 54 years

28.17

55 years and over

29.12

15 to 24 years

15.81

25 to 54 years

30.00

55 years and over

29.30

15 to 24 years

14.11

25 to 54 years

24.89

55 years and over

24.19

1

Territory age- and sex-specific wage rates were unavailable from the Labour Force Survey, average territoryspecific wage rate was used instead, see table 16.
http://www5.statcan.gc.ca/cansim/a26?lang=eng&id=2820074
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Table 16. Average provincial wage rates (2016 CAD).
Average wage rate
(2016 CAD)

Province
Newfoundland

24.90

Prince Edward Island

20.43

Nova Scotia

21.55

New Brunswick

21.51

Quebec

23.06

Ontario

23.68

Manitoba

22.72

Saskatchewan

25.60

Alberta

26.52

British Columbia

23.85

Yukon

26.55

Northwest Territories

31.28

Nunavut

30.74

http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr80-eng.htm

Table 17. Sensitivity analysis of direct, indirect, and total costs
incurred (2016 CAD), for all donors (n = 912) using 2016
provincial wage rates.
Costs incurred, all donors (CAD)
Cost type
Mean (SD)

Median (25th-75th percentile)

Direct

2110 (2505)

1302 (581-2674)

Indirect

2424 (4882)

22 (0-2617)

Total

4535 (5573)

2565 (1066-5916)
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Table 18. Inflation rates used to standardize costs to
the year 2016 using Canada's Consumer Price Index.
Year of Surgery

Inflation Rate

2009

10.9%

2010

9.3%

2011

6.6%

2012

5.2%

2013

4.3%

2014

2.5%

2015

1.4%

http://www.statcan.gc.ca/tables-tableaux/sumsom/l01/cst01/econ46a-eng.htm
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Appendix F: Multiple imputation diagnostics

Figure 8. Distribution of imputed, observed, and completed values for "Number of Trips" across all 20 imputation sets. 100 of 912 values were imputed.
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Figure 9. Distribution of imputed, observed, and completed values for "Hospital Accommodation Cost" across all 20 imputation sets. 103 of 912 values were
imputed.
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Figure 10. Distribution of imputed, observed, and completed values for "Nights in Hotels" across all 20 imputation sets. 95 of 912 values were imputed.
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Figure 11. Distribution of imputed, observed, and completed values for "Friends/Family Accommodation Costs" across all 20 imputation sets. 99 of 912
values were imputed.
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Figure 12. Distribution of imputed, observed, and completed values for “Parking Costs” across all 20 imputation sets. 104 of 912 values were imputed.
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Figure 13. Distribution of imputed, observed, and completed values for "Days Off Without Pay" across all 20 imputation sets. 107 of 912 values were imputed.
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Figure 14 Distribution of imputed, observed, and completed values for "Unable to Perform Household Activities Costs" across all 20 imputation sets. 119 of
912 values were imputed.
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Figure 15. Distribution of imputed, observed, and completed values for "Unable to Care for Dependents Costs" across all 20 imputation sets. 118 of 912
values were imputed.
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Figure 16. Distribution of imputed, observed, and completed values for "Medication Costs" across all 20 imputation sets. 104 of 912 values were imputed.

107

Appendix G: GLM – model diagnostics and goodness of fit
a)

b)

Figure 17. a) GLM diagnostic output b) Normal probability plot assessing deviance residuals for models estimating effect of donationtype groups on direct costs.
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a)

b)

Figure 18. a) GLM diagnostic output b) Normal probability plot assessing deviance residuals for models estimating effect of donation-type
groups on indirect costs.
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a)

b)

Figure 19. a) GLM diagnostic output b) Normal probability plot assessing deviance residuals for models estimating effect of donation-type
groups on total costs.
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a)

b)

Figure 20. a) GLM diagnostic output b) Normal probability plot assessing deviance residuals for models estimating effect of relationship-type
groups on direct costs.
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a)

b)

Figure 21. a) GLM diagnostic output b) Normal probability plot assessing deviance residuals for models estimating effect of relationship-type
groups on indirect costs.
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a)

b)

Figure 22. a) GLM diagnostic output b) Normal probability plot assessing deviance residuals for models estimating effect of relationship-type
groups on total costs.
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Appendix H: Complete-case analyses
Table 19. Complete-case analysis of direct resource use for all donors, from 3-month economic assessment (2016 CAD).

Cost category

Travel

Accommodation

Medication
1

Resource use3

Costs for donors reporting expense
(CAD)

Costs for all donors, n = 912
(CAD)

Donors
reporting
resource,
n (%)2

Units

Median
(IQR)

Average (SD)

Median
(IQR)

Average (SD)

Median (IQR)

Ground travel

726 (89%)

# Return trips

10 (7-15)

1070 (1584)

500 (190-1192)

957 (1534)

402 (127-1116)

Air travel

173 (21%)

# Return trips

1 (1-2)

637 (458)

562 (324-744)

134 (334)

0 (0-0)

Parking1

716 (89%)

# Days of
paid parking

7 (4-11)

139 (296)

104 (55-164)

122 (281)

89 (42-158)

Family and
friends1

287 (35%)

# Nights

6 (3-12)

766 (1439)

315 (158-765)

197 (802)

0 (0-31)

Non-hospital
paid

339 (41%)

# Nights

5 (2-8)

1150 (1818)

748 (299-1347)

477 (1300)

0 (0-565)

Hospital1

368 (45%)

# Nights

4 (3-5)

295 (530)

105 (47-336)

134 (386)

0 (0-103)

Pain medication
or antibiotics1

629 (77%)

Drugs taken
(yes/no)

n/a

69 (213)

33 (21-63)

43 (171)

16 (0-46)

Description

Self-reported costs (not micro-costed).
Denominator varies with participant response rate for each variable (Table 3); among donors reporting resource use (even if no out-of-pocket expenses were incurred).
3 In donors reporting the outcome.
2
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Table 20. Complete-case analysis of indirect resource use for all donors, from 3-month economic assessment (2016 CAD).

Cost category

Lost income

Lost productivity

Donors
reporting
resource,
n (%)2

Number of days3

Unable to work if
employed

634 (78%)

35 (15-60)

Unpaid time off
work

251 (31%)

30 (10-56)

Unable to perform
household activities1

641 (79%)

Unable to care for
dependants1

411 (51%)

Description

Median (IQR)

Costs in donors reporting expense
(CAD)

Costs for all donors, n = 912
(CAD)

Average (SD)

Median (IQR)

Average (SD)

Median (IQR)

7827 (7439)

5974 (2481-11,748)

2441 (5511)

0 (0-2110)

16 (10-30)

762 (3009)

320 (205-532)

116 (1203)

0 (0-0)

15 (9-30)

981 (2194)

328 (158-631)

95 (739)

0 (0-0)

1

Self-reported costs (not micro-costed).
Denominator varies with participant response rate for each variable (Table 3); among donors reporting resource use (even if no out-of-pocket expenses were incurred).
3 In donors reporting the outcome.
2

Table 21. Complete-case direct, indirect, and total incurred
costs, all donors (2016 CAD).
Costs incurred (CAD)
Cost type
Mean (SD)

Median (IQR)

Direct (n = 785)

2064 (2531)

1255 (543-2603)

Indirect (n = 780)

2595 (5652)

0 (0-2368)

Total (n = 757)

4443 (5782)

2252 (891-5581)
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Table 22. Complete-case unadjusted direct, indirect, and total costs (2016 CAD) incurred by living kidney donors, by donation-type group.
All Other Donors

Non-Directed Donors

Kidney Paired Donors

All Other Donors

Non-Directed
Donors

Kidney Paired
Donors

Mean
(95% CI)1

MD
(95% CI)2

Mean
(95% CI)1

MD
(95% CI)2

Mean
(95% CI)1

MD
(95% CI)2

Median (IQR)

Median (IQR)

Median (IQR)

Direct3

2013
(1833 to 2247)

ref

2140
(1550 to 3636)

126
(-776 to 1030)

2345
(2030 to 2710)

331
(-257 to 919)

1175
(489-2505)

2139
(690-2709)

2073
(1020-3241)

Indirect3

2686
(2250 to 3173)

ref

2579
(1292 to 5360)

-107
(-2004 to 1790)

2044
(1424 to 2994)

-642
(-1598 to 314)

0
(0-2411)

0
(0-2619)

0
(0-2080)

Total3

4728
(4249 to 5286)

ref

4778
(3081 to 7665)

50
(-2177 to 2278)

4457
(3681 to 5625)

-271
(-1542 to 1001)

2152
(859-5886)

2678
(1008-4772)

2914
(1578-5869)

Cost type

1

Bootstrapped mean and 95% confidence interval.
MD = mean difference, as marginal effect from univariate generalized linear model.
3
Number of donors varies by response rate (Table 20); Direct (Others = 644, Non-Directed = 35, Paired = 105); Indirect (Others = 640, Non-Directed = 35, Paired = 105); Total (Others = 621,
Non-Directed = 34, Paired = 102).

2

Table 23. Complete-case unadjusted direct, indirect, and total costs (2016 CAD) incurred by living kidney donors, by relationship-type group.
Spousal Donors

Closely Related Donors

Unrelated Donors

Spousal Donors

Closely Related
Donors

Unrelated
Donors

Mean
(95% CI)1

MD
(95% CI)2

Mean
(95% CI) 1

MD
(95% CI)2

Mean
(95% CI) 1

MD
(95% CI)2

Median (IQR)

Median (IQR)

Median (IQR)

Direct4

2468
(1998 to 3312)

ref

1884
(1659 to 2173)

-584
(-1191 to 24)

1940
(1629 to 2382)

-528
(-1189 to 133)

1322
(529-2523)

1116
(486-2555)

1161
(465-2376)

Indirect4

3012
(2058 to 4779)

ref

2892
(2311 to 3550)

-120
(-1449 to 1210)

2041
(1535 to 2888)

-972
(-2302 to 359)

0
(0-2597)

0
(0-2422)

0
(0-2129)

Total4

5471
(4286 to 7279)

ref

4820
(4175 to 5519)

-650
(-2166 to 865)

4017
(3306 to 4939)

-1454
(-3031 to 123)

1879
(1022-6846)

2187
(787-5831)

2215
(904-5165)

Cost type

1

Bootstrapped mean and 95% confidence interval.
MD = mean difference, as marginal effect from univariate generalized linear model.
3
Among donors not participating in non-directed or kidney paired donations.
4
Number of donors varies by response rate (Table 20); Direct (Spousal = 126, Closely = 341, Unrelated = 177); Indirect (Spousal = 121, Closely = 347, Unrelated = 172); Total (Spousal = 119,
Closely = 334, Unrelated = 168).
2
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Table 24. Complete-case adjusted1 average marginal effects of demographic variables on direct, indirect, and total
costs (2016 CAD) incurred by living kidney donors (n = 821).
Direct costs (CAD)

Indirect costs (CAD)

Total costs (CAD)

Variable
Marginal effect
(95% CI)

p

Marginal effect
(95% CI)

p

Marginal effect
(95% CI)

p

Donation-type
All other donors

ref

ref

ref

Non-directed donors

-246 (-867 to 376)

0.44

-421 (-1328 to 486)

0.36

-980 (-1959 to 0)

0.05

Kidney paired donors

369 (-118 to 856)

0.14

39 (-800 to 877)

0.93

483 (-618 to 1584)

0.39

Relationship-type2
Spousal donors

ref

ref

ref

Closely related donors

-333 (-797 to 131)

0.16

-749 (-2241 to 744)

0.33

-1043 (-2311 to 224)

0.11

Unrelated donors

-77 (-921 to 767)

0.86

-1443 (-2458 to -428)

0.005

-1528 (-2818 to -238)

0.02

<0.001

-588 (-1461 to 285)

0.19

2019 (1105 to 2934)

0.28

-6 (-858 to 846)

0.99

104 (-779 to 988)

Distance from centre
<100 km

ref

≥100 km

2478 (2040 to 2915)

ref

ref
<0.001

Sex
Male
Female

ref
-260 (-728 to 208)

ref

ref
0.82

Age
18 to 35

ref

ref

ref

35 to 54

739 (453 to 1026)

<0.001

-788 (-2133 to 557)

0.25

63 (-1299 to 1426)

0.93

55+

1029 (540 to 1517)

<0.001

-1650 (-2756 to -543)

0.003

-221 (-1267 to 824)

0.68

0.56

-625 (-1656 to 406)

0.24

-311 (-1255 to 633)

Race
White
Non-White

ref
-143 (-616 to 332)

ref

Ref
0.52
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Direct costs (CAD)

Indirect costs (CAD)

Total costs (CAD)

Variable
Marginal effect
(95% CI)

p

Marginal effect
(95% CI)

p

Marginal effect
(95% CI)

p

Income
<$20,000

ref

ref

ref

$20,000 to $40,000

1314 (617 to 2011)

<0.001

890 (-2193 to 3973)

0.57

2674 (-310 to 5657)

0.08

$40,000 to $60,000

1208 (594 to 1822)

<0.001

-855 (-3944 to 2234)

0.59

603 (-2406 to 3613)

0.69

$60,000 to $80,000

1254 (594 to 1915)

<0.001

-308 (-3557 to 2941)

0.85

1309 (-1532 to 4151)

0.37

$80,000 to $100,000

623 (166 to 1081)

0.008

-1730 (-4614 to 1154)

0.24

-572 (-3248 to 2285)

0.70

>$100,000

597 (233 to 961)

0.001

-1708 (-4260 to 844)

0.19

-771 (-2963 to 1421)

0.49

Employment status
Employed
Unemployed

ref
-820 (-1424 to -215)

ref
0.008

-1822 (-3103 to -541)

ref
0.005

-2357 (-3969 to -746)

0.004
<0.001
0.98

Retired

-246 (-649 to 157)

0.23

-2347 (-3004 to -1689)

<0.001

-2157 (-3030 to 1284)

Other

267 (-544 to 1007)

0.56

-101 (-2217 to 2016)

0.93

-26 (-2325 to 2273)

Province of transplant
centre
Ontario

ref

Alberta

-565 (-1022 to -109)

0.02

161 (-1304 to 1626)

0.83

-125 (-1575 to 1326)

0.87

142 (-258 to 542)

0.49

-371 (-1355 to 614)

0.46

-54 (-1076 to 968)

0.92

British Columbia
Manitoba

ref

ref

-966 (-1494 to -439)

<0.001

385 (-2071 to 2842)

0.76

-368 (-2611 to 1876)

0.75

Nova Scotia

-185 (-811 to 442)

0.56

74 (-2279 to 2427)

0.95

50 (-2363 to 2463)

0.97

Quebec

902 (-406 to 2211)

0.18

917 (-1721 to 3555)

0.50

1940 (-1040 to 4920)

0.20

1 Adjusted

for age, sex, income, Clavien score, and transplant centre.
2 Among donors not participating in non-directed or kidney paired donations.
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Appendix I: STROBE checklist for reporting of cohort studies
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